[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 758
1. Ishikura K, Takamura T, Takeshita Y, Nakagawa A, Imaizumi N, Misu H, Taji K, Kasahara K, Oshinoya Y, Suzuki S, Ooi A, Kaneko S: Cushing's syndrome and big IGF-II associated hypoglycaemia in a patient with adrenocortical carcinoma. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's syndrome and big IGF-II associated hypoglycaemia in a patient with adrenocortical carcinoma.
  • A 41-year-old woman had a general health examination and was diagnosed with a non-functioning adrenocortical carcinoma (ACC).
  • Initially, she developed adrenal insufficiency and was treated with hydrocortisone.
  • We identified big IGF-II, a primary hormonal mediator of non-islet cell tumour hypoglycaemia (NICTH), in the serum and tumour using western blotting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22461853.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027795
  •  go-up   go-down


2. Suyama K, Beppu T, Isiko T, Sugiyama S, Matsumoto K, Doi K, Masuda T, Ohara C, Takamori H, Kanemitsu K, Hirota M, Baba H: Spontaneous rupture of adrenocortical carcinoma. Am J Surg; 2007 Jul;194(1):77-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous rupture of adrenocortical carcinoma.
  • Massive hemorrhage from an adrenocortical carcinoma seldom occurs in the retroperitoneal or abdominal cavity.
  • We report a case of spontaneous rupture of primary adrenocortical carcinoma occurring in an adolescent.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560914.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Pradeep PV, Mishra AK, Aggarwal V, Bhargav PR, Gupta SK, Agarwal A: Adrenal cysts: an institutional experience. World J Surg; 2006 Oct;30(10):1817-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal cysts: an institutional experience.
  • INTRODUCTION: Adrenal cysts are rare clinical entities.
  • We report our institutional experience with adrenal cysts and also assess various management options.
  • MATERIAL AND METHODS: Over the past 15 years the Department of Endocrine Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, has had seven cases of adrenal cysts, of which two were functional: one patient had Cushing's syndrome and the other patient had pheochromocytoma.
  • It is generally agreed that a hormonal work-up is necessary in all cases of adrenal cysts to rule out a sub-clinical disease.
  • Adrenal neoplasms, including adrenocortical carcinomas, can be associated with cysts that are benign in appearance.
  • However, surgical excision provides a definite histopathological diagnosis and also removes the fear of future complications such as hemorrhage into the cyst and local pressure effects due to the tumor.
  • CONCLUSIONS: Given that the adrenals are a vascular gland and taking into consideration the possibilities of bleeding and complications in the cyst, our treatment of choice is the elective excision of adrenal cysts.
  • [MeSH-major] Academies and Institutes / statistics & numerical data. Adrenal Gland Diseases / diagnosis. Adrenal Gland Diseases / surgery. Adrenalectomy / methods. Cysts / diagnosis. Cysts / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. India. Laparoscopy. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Mar;173(3):915-7 [15711326.001]
  • [Cites] Ann Surg. 1974 Feb;179(2):186-9 [4811049.001]
  • [Cites] J Urol. 1983 May;129(5):1031-3 [6854747.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1537-44 [15378490.001]
  • [Cites] Radiology. 1989 Oct;173(1):107-10 [2675177.001]
  • [Cites] J Endocrinol Invest. 1998 Feb;21(2):109-14 [9585385.001]
  • [Cites] Chirurgia (Bucur). 2004 Jul-Aug;99(4):255-8 [15560563.001]
  • [Cites] Acta Cytol. 1984 May-Jun;28(3):269-82 [6587703.001]
  • [Cites] Int Surg. 2005 Apr-Jun;90(2):78-80 [16119709.001]
  • [Cites] Ann Acad Med Singapore. 1999 Nov;28(6):863-6 [10672405.001]
  • [Cites] Am Surg. 1999 Feb;65(2):151-63 [9926751.001]
  • [Cites] Int Urol Nephrol. 1998;30(4):369-76 [9821036.001]
  • (PMID = 16983481.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Nader N, Raverot G, Emptoz-Bonneton A, Déchaud H, Bonnay M, Baudin E, Pugeat M: Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab; 2006 Jun;91(6):2165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Human hepatoma cell lines (HepG2), lacking estrogen receptor (ER)-alpha, and Hep89, stably transfected by ERalpha, were used.
  • PATIENTS AND OTHER PARTICIPANTS: The study included 10 male patients with recurrent adrenal carcinoma, receiving mitotane (4-6.5 g daily) for more than 6 months.
  • In the HepG2 cell line, 17beta-estradiol (E2) or o,p'-DDD treatment had no effect on mRNA or SHBG/CBG concentrations.
  • In contrast, in the Hep89 cell line, E2 increased concentrations of SHBG (r = 0.44, P < 0.0001) and CBG (r = 0.585, P < 0.0001) secreted into culture media in a dose-dependent manner. o,p'-DDD significantly increased SHBG (150% vs. control, P < 0.05) and CBG (184% vs. control, P < 0.05) production by Hep89 cells, at a concentration of 2 x 10(-5) m.
  • [MeSH-minor] Adrenal Gland Neoplasms / blood. Adrenal Gland Neoplasms / drug therapy. Estradiol / pharmacology. Estrogen Receptor alpha / drug effects. Estrogen Receptor alpha / physiology. Humans. Liver / metabolism. Male. Promoter Regions, Genetic. RNA, Messenger / analysis. Transcription, Genetic. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. MITOTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551731.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor alpha; 0 / RNA, Messenger; 0 / Sex Hormone-Binding Globulin; 4TI98Z838E / Estradiol; 78E4J5IB5J / Mitotane; 9010-38-2 / Transcortin
  •  go-up   go-down


5. Lee JE: Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med; 2007 Sep 20;357(12):1258; author reply 1259
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant mitotane in adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • (PMID = 17891836.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


6. Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE: Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery; 2007 Dec;142(6):867-75; discussion 867-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
  • BACKGROUND: Adrenal cortical carcinoma (ACC) is a rare disease in which recurrence after surgery is common.
  • RESULTS: The median disease-free survival for all 186 patients was 12 months and the median overall survival (OS) was 37 months.
  • For patients with stable or responding disease to mitotane, the median OS from date of recurrence was 18 months, compared with 9 months (P = .01) for those who progressed.
  • CONCLUSIONS: Patients with recurrent ACC who have stable or responding disease to mitotane have a more favorable prognosis than those who progress.
  • Mitotane should be considered in most patients with recurrent ACC, including as preoperative therapy for those with recurrent disease considered for surgical resection.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / surgery. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Predictive Value of Tests. Prognosis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063070.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


7. Geiss HK, Feldhues R, Niemann S, Nolte O, Rieker R: Landouzy septicemia (sepsis tuberculosa acutissima) due to Mycobacterium microti in an immunocompetent man. Infection; 2005 Oct;33(5-6):393-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the following, we describe the case of a previously healthy man who underwent laparotomy for suspected adrenal carcinoma.
  • No other pathogen could be isolated during the clinical course, which finally led to the diagnosis of Landouzy septicemia (sepsis tuberculosa acutissima).

  • MedlinePlus Health Information. consumer health - Mycobacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258876.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Heye S, Woestenborghs H, Van Kerkhove F, Oyen R: Adrenocortical carcinoma with fat inclusion: case report. Abdom Imaging; 2005 Sep-Oct;30(5):641-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma with fat inclusion: case report.
  • Adrenocortical carcinoma is a rare tumor that arises from the adrenal cortex, with an estimated incidence of 0.5% to 2% per 1 million patients yearly.
  • Although some fat content can be expected in hormonally active adrenocortical carcinomas, areas of 100% fat are extremely rare.
  • We present a case of an adrenocortical carcinoma with a small focus of pure fat depicted on magnetic resonance imaging.
  • [MeSH-major] Adipose Tissue / pathology. Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15688105.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


9. Fardella CE, Mosso LM, Carvajal CA: [Primary aldosteronism]. Rev Med Chil; 2008 Jul;136(7):905-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the cardiovascular system, aldosterone modifies endothelial and smooth muscle cell response, increasing cardiovascular risk in a blood pressure-independent way.
  • This ratio increases along with the severity of the hypertensive disease.
  • The diagnostic work up of PA should confirm the autonomy of aldosterone secretion from the renin-angiotensin system and should differentiate the clinical subtypes of the disease.
  • Other causes are familial hyperaldosteronism (FH) type I (glucocorticoid-remediable aldosteronism), FH-II (non glucocorticoid-remediable aldosteronism), primary adrenal hyperplasia and adrenal carcinoma.
  • This article reviews the prevalence, diagnosis and treatment of PA and also the clinical, biochemical and genetic characteristics of its different subtypes.
  • [MeSH-major] Aldosterone / metabolism. Hyperaldosteronism / diagnosis. Hypertension / etiology

  • Genetic Alliance. consumer health - Primary aldosteronism.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949169.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Chile
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone; EC 3.4.23.15 / Renin
  • [Number-of-references] 61
  •  go-up   go-down


10. Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C, Duh QY, Clark OH, Kebebew E: Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg; 2008 Sep;143(9):841-6; discussion 846
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling.
  • HYPOTHESIS: The gene expression profiles of benign and malignant adrenocortical tumors are different.
  • PATIENTS: Eighty-five patients with benign adrenocortical tumors (n = 74) and adrenocortical carcinoma (n = 11).
  • INTERVENTION: Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) in 89 adrenocortical tissue samples (11 malignant and 78 benign).
  • The criteria for differentially expressed genes between benign and malignant adrenocortical tumors were a false discovery rate of less than 5% and an adjusted P < .01.
  • Fifteen genes were downregulated and 22 were upregulated in adrenocortical carcinoma.
  • Of the 37 genes validated by RT-PCR, 22 were significantly differentially expressed between benign and malignant adrenocortical tumors (P < .05).
  • Five of these 22 genes had an AUC of 0.80 or greater (the AUC for IL13RA2 was 0.90; HTR2B, 0.87; CCNB2, 0.86; RARRES2, 0.86; and SLC16A9, 0.80), indicating high diagnostic accuracy for distinguishing benign from malignant adrenocortical tumors.
  • CONCLUSION: We identified 37 genes that are dysregulated in adrenocortical carcinoma, and several of the differentially expressed genes have excellent diagnostic accuracy for distinguishing benign from malignant adrenocortical tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Biomarkers, Tumor. Gene Expression Profiling. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adrenal Cortex. Adult. Aged. Area Under Curve. Chemokines / metabolism. Cyclin B / metabolism. Cyclin B2. Female. Humans. Intercellular Signaling Peptides and Proteins. Interleukin-13 Receptor alpha2 Subunit / metabolism. Male. Middle Aged. Monocarboxylic Acid Transporters / metabolism. Oligonucleotide Array Sequence Analysis. Pituitary ACTH Hypersecretion / etiology. ROC Curve. Receptor, Serotonin, 5-HT2B / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794420.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCNB2 protein, human; 0 / Chemokines; 0 / Cyclin B; 0 / Cyclin B2; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / Monocarboxylic Acid Transporters; 0 / Receptor, Serotonin, 5-HT2B; 0 / chemerin protein, human
  •  go-up   go-down


11. Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E: Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg; 2006 Mar;202(3):423-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy?
  • STUDY DESIGN: Adrenocortical carcinomas (ACC) recorded in the Surveillance, Epidemiology, and End Results (SEER) database (1988 to 2000) were compared with benign functional or nonfunctional adrenal cortical adenomas (excluding aldosteronomas) operated on at our institution between January 1, 1993, and July 1, 2003.
  • RESULTS: We identified 457 patients with ACC and 47 patients with adrenal cortical adenomas; 376 and 44 neoplasms, respectively, had tumor size data available.
  • For ACC presenting with local disease, the sensitivity, specificity, and likelihood ratios of tumor size to predict malignancy were 96%, 52%, and 2.0, respectively, for tumors > or = 4 cm; 90%, 80%, and 4.4 for tumors > or = 6 cm; 77%, 95%, and 16.9 for tumors > or = 8 cm; and 55%, 98%, and 24.4 for tumors > or = 10 cm.
  • Assuming a pretest probability of malignancy of 5%, the likelihood ratios derived from this study yield a posttest probability of 10%, 19%, and 47% for cancer in adrenal cortical tumors > or = 4 cm, > or = 6 cm, and > or = 8 cm, respectively.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prevalence. Probability. Prognosis. Retrospective Studies. Risk Assessment. SEER Program / statistics & numerical data. Severity of Illness Index

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500246.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Abadie C, Bernard F, Netchine I, Sanlaville D, Roque A, Rossignol S, Coupier I: Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation. Eur J Med Genet; 2010 Nov-Dec;53(6):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This syndrome is a multigenic disorder caused by dysregulation of imprinted growth regulatory genes in the 11p15.5 region.
  • The most commonly reported tumours in this syndrome are tumours of embryologic origin such as Wilms tumours, hepatoblastomas, neuroblastomas, rhabdomyosarcomas and adrenocortical carcinomas.
  • We report the case of a 10-year-old patient diagnosed with BWS, harbouring a CDKN1C (p57(KIP2)) mutation, who developed a T-type acute lymphoblastic leukaemia.
  • We discuss the possibility of a link between BWS and leukaemia via one of the few known negative regulator of hematopoiesis, the transforming growth factor beta pathway, depending upon the up-regulation of CDKN1C.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / genetics. Cyclin-Dependent Kinase Inhibitor p57 / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20826236.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57
  •  go-up   go-down


13. Barzon L, Masi G, Fincati K, Pacenti M, Pezzi V, Altavilla G, Fallo F, Palù G: Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma. Eur J Endocrinol; 2005 Nov;153(5):629-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma.
  • OBJECTIVE: Adrenocortical tumors may originate from the zona glomerulosa, zona fasciculata, or zona reticularis and be associated with syndromes due to overproduction of mineralocorticoids, glucocorticoids, or androgens respectively.
  • We report an unusual case of recurrent adrenocortical carcinoma (ACC), which seems to contradict the paradigm of functional adrenal zonation.
  • METHODS AND RESULTS: Extensive pathologic examination showed that this shift in steroid hormone production was paralleled by an attenuation of tumor cell atypia and polymorphism, whereas gene expression profile analysis demonstrated a change in expression of adrenal steroidogenic enzymes.
  • Moreover, cancer progression was associated with overexpression of the inhibin-alpha subunit, which could have contributed to the phenotypic changes.
  • CONCLUSIONS: This case of recurrent ACC demonstrates that adrenocortical cells can reverse their differentiation program during neoplastic progression and change their specific hormone synthesis, as a consequence of modifications in the expression profile of steroidogenic enzymes and cofactors.
  • These findings, besides opening new perspectives to study adrenocortical cell plasticity and potential, demonstrate how conventional clinical and pathologic evaluation can be combined with genomic analysis in order to dissect thoroughly the biology of cancer.


14. Białas M, Okoń K, Stachura J: Primary adrenal tumors--a 16-year experience in a single institution. Pol J Pathol; 2008;59(2):101-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adrenal tumors--a 16-year experience in a single institution.
  • The incidence of primary adrenal gland tumors observed at the Pathology Department, Cracow, in the period of 16 years was examined.
  • The frequency of adrenal lesion in males and females was studied and compared.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Adenoma / surgery. Adrenal Cortex / pathology. Adrenal Cortex Neoplasms / epidemiology. Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / epidemiology. Adrenocortical Carcinoma / pathology. Adrenocortical Carcinoma / surgery. Humans. Hyperplasia / epidemiology. Hyperplasia / pathology. Hyperplasia / surgery. Pheochromocytoma / epidemiology. Pheochromocytoma / pathology. Pheochromocytoma / surgery. Poland / epidemiology. Sex Factors. World Health Organization

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669176.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


15. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, Yuan H, Perry DA, Keiser J: Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology; 2009 May;150(5):2211-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The direct effects of torcetrapib and related molecules on adrenal steroid production were assessed in cell culture using the H295R as well as the newly developed HAC15 human adrenal carcinoma cell lines.
  • Torcetrapib induced the synthesis of both aldosterone and cortisol in these two in vitro cell systems.
  • Transcription profiling indicated that torcetrapib and angiotensin II share overlapping pathways in regulating adrenal steroid biosynthesis.
  • Consistent with intracellular calcium being the key mediator of torcetrapib's effect in adrenal cells, calcium channel blockers completely blocked torcetrapib-induced corticoid release and calcium increase.
  • The results indicate that the pressor and adrenal effects observed with torcetrapib and related molecules are independent of CETP inhibition.
  • [MeSH-minor] Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / pathology. Anticholesteremic Agents / adverse effects. Anticholesteremic Agents / chemistry. Anticholesteremic Agents / pharmacology. Blood Pressure / drug effects. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Cell Line, Tumor. Cytochrome P-450 CYP11B2 / genetics. Cytochrome P-450 CYP11B2 / metabolism. Drug Evaluation, Preclinical. Gene Expression Regulation, Neoplastic / drug effects. Humans. Intracellular Fluid / drug effects. Intracellular Fluid / metabolism. Models, Biological. Steroid 11-beta-Hydroxylase / genetics. Steroid 11-beta-Hydroxylase / metabolism. Structure-Activity Relationship


16. Huang H, Fojo T: Adjuvant mitotane for adrenocortical cancer--a recurring controversy. J Clin Endocrinol Metab; 2008 Oct;93(10):3730-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant mitotane for adrenocortical cancer--a recurring controversy.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Carcinoma / drug therapy. Mitotane / adverse effects. Mitotane / therapeutic use

  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] N Engl J Med. 2007 Sep 20;357(12):1256-7; author reply 1259 [17881760.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1385-92 [11745214.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jun;85(6):2234-8 [10852456.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jan;20(1):47-53 [6537915.001]
  • [Cites] Am J Med. 1966 Oct;41(4):572-80 [5923598.001]
  • [Cites] JAMA. 1973 Mar 5;223(10):1109-12 [4739370.001]
  • [Cites] J Steroid Biochem. 1973 Nov;4(6):585-91 [4789318.001]
  • [Cites] Cancer. 1978 Nov;42(5):2177-81 [719602.001]
  • [CommentIn] J Clin Endocrinol Metab. 2009 Jun;94(6):1879-80 [19494162.001]
  • [CommentOn] J Clin Endocrinol Metab. 2000 Jun;85(6):2234-8 [10852456.001]
  • (PMID = 18842984.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  • [Other-IDs] NLM/ PMC2579650
  •  go-up   go-down


17. Patalano A, Brancato V, Mantero F: Adrenocortical cancer treatment. Horm Res; 2009 Jan;71 Suppl 1:99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical cancer treatment.
  • BACKGROUND: With a reported incidence of 1 to 2 cases per million, adrenocortical cancer (ACC) is a rare disease with poor prognosis.
  • Although most cases of ACC are of sporadic origin, they may also occur as part of a congenital or familial disease in which the genetic abnormalities are well established.
  • New treatments, such as insulin-like growth factor I receptor antibodies, tyrosine kinase inhibitors and other antiangiogenic compounds, are now being intensively investigated to identify better therapies for this extremely severe malignant neoplasia.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / therapy
  • [MeSH-minor] Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnostic Imaging / methods. Genetic Predisposition to Disease. Humans. Mitotane / administration & dosage. Prognosis. Streptozocin / administration & dosage. Syndrome

  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153517.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5W494URQ81 / Streptozocin; 78E4J5IB5J / Mitotane
  • [Number-of-references] 29
  •  go-up   go-down


18. Kazaryan AM, Marangos IP, Rosseland AR, Røsok BI, Villanger O, Pinjo E, Pfeffer PF, Edwin B: Laparoscopic adrenalectomy: Norwegian single-center experience of 242 procedures. J Laparoendosc Adv Surg Tech A; 2009 Apr;19(2):181-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The last 15 years have been characterized by a rapid expansion of minimally invasive surgery as treatment for adrenal diseases.
  • Of these, 192 patients were operated on for benign lesions, 23 for malignant lesions, and in 5 cases "en bloc" adrenalectomies were performed.
  • Benign lesions included 136 hormonally active lesions (41 pheochromocytomas, 48 Conn adenomas, 25 Cushing adenomas, and 18 patients with Cushing's disease) and 56 with hormonally inactive lesions (among them, 47 nonfunctional adenomas).
  • Malignant lesions included 16 adrenal metastases and 7 adrenocortical carcinomas.
  • The number of complications did not differ between the types of adrenal pathology.
  • Per- and postoperative parameters were homogeneous among patients with different adrenal lesions.
  • The patients with adrenocortical carcinoma had a distinctive intraoperative course with an evidently longer operative time and higher blood loss.
  • Hospital stay was the only postoperative parameter where a difference was found between patients with different adrenal lesions.
  • The patients with carcinoma, pheochromocytoma, and Cushing's disease had the longest median postoperative stay, respectively, 5 (range, 2-6), 3 (range, 1-15), and 3 (range, 2-6) days.
  • CONCLUSIONS: Laparoscopic adrenalectomy is a safe, effective procedure providing improved fast and uncomplicated patient recovery independent of the type of adrenal lesion.
  • [MeSH-major] Adrenal Gland Diseases / surgery. Adrenalectomy / methods. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216698.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kvacheniuk AN: [Surgical treatment of adrenocortical cancer: significance of systematic lymphodissection]. Klin Khir; 2008 Mar;(3):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of adrenocortical cancer: significance of systematic lymphodissection].
  • Comparative efficacy of radical methods of surgical intervention for adrenocortical cancer (ACC) with lymphodissection (LD) and without it was studied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18680995.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


20. Stritzel S, Mischke R, Philipp U, Kleinschmidt S, Wohlsein P, Stock KF, Distl O: [Familial canine pituitary-dependent hyperadrenocorticism in wirehaired Dachshunds]. Berl Munch Tierarztl Wochenschr; 2008 Sep-Oct;121(9-10):349-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Canine pituitary hyperadrenocorticism (Cushing's disease) caused by neoplasia of the corticotrope cells is one of the most common endocrine diseases especially in smaller dog breeds.
  • Cushing's disease was diagnosed in eleven wire-haired Dachshunds and for further six wire-haired Dachshunds Cushing's disease was suspected on the basis of clinical signs.
  • The main lesions consisted of atrophic dermatosis with alopecia, increase of activity of liver enzymes in plasma and bilateral adrenocortical hyperplasia and therefore corresponded to the typical signs of a secondary hyperadrenocorticism.
  • A rather unusual finding was the pituitary carcinoma in one of these dogs.
  • [MeSH-major] Adrenal Cortex Neoplasms / veterinary. Adrenocortical Hyperfunction / veterinary. Dog Diseases / genetics. Pedigree
  • [MeSH-minor] Animals. Breeding. Dogs. Female. Genes, MDR. Genetic Predisposition to Disease. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18822606.001).
  • [ISSN] 0005-9366
  • [Journal-full-title] Berliner und Münchener tierärztliche Wochenschrift
  • [ISO-abbreviation] Berl. Munch. Tierarztl. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Miyoshi I, Kubota T, Saito T, Kobayashi M, Toi M, Ohtsuki Y, Taguchi H: Psammoma bodies in lung cancer. Intern Med; 2006;45(5):335-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psammoma bodies in lung cancer.
  • [MeSH-major] Adrenocortical Carcinoma / pathology. Inclusion Bodies / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma. Aged. Fatal Outcome. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596008.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Wittekind C: [TNM 2010. What's new?]. Pathologe; 2010 Oct;31 Suppl 2:153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the seventh edition of the TNM Classification of Malignant Tumours there are several entirely new classifications: upper aerodigestive mucosal melanoma, gastrointestinal stromal tumour, gastrointestinal carcinoid (neuroendocrine tumour), intrahepatic cholangiocarcinoma, Merkel cell carcinoma, uterine sarcomas, and adrenal cortical carcinoma.
  • Significant modifications concern carcinomas of the oesophagus, oesophagogastric junction, stomach, appendix, biliary tract, lung, skin, prostate and ophthalmic tumours, which will be not addressed in this article.
  • [MeSH-minor] Adrenal Cortex Neoplasms / classification. Adrenal Cortex Neoplasms / pathology. Bile Duct Neoplasms / classification. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoid Tumor / classification. Carcinoid Tumor / pathology. Carcinoma, Merkel Cell / classification. Carcinoma, Merkel Cell / pathology. Cholangiocarcinoma / classification. Cholangiocarcinoma / pathology. Digestive System Neoplasms / classification. Digestive System Neoplasms / pathology. Female. Gastrointestinal Stromal Tumors / classification. Gastrointestinal Stromal Tumors / pathology. Humans. Respiratory Tract Neoplasms / classification. Respiratory Tract Neoplasms / pathology. Sarcoma / classification. Sarcoma / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology. Uterine Neoplasms / classification. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Ann Surg. 2010 Jan;251(1):46-50 [20032718.001]
  • [Cites] Cancer. 2010 Aug 15;116(16):3763-73 [20564099.001]
  • [Cites] Virchows Arch. 2010 Jun;456(6):595-7 [20422210.001]
  • [Cites] Dis Esophagus. 2009;22(1):1-8 [19196264.001]
  • [Cites] Biostatistics. 2009 Oct;10(4):603-20 [19502615.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • [Cites] Pathologe. 2010 Sep;31(5):374-8 [20703482.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Nov;95(11):4925-32 [20668036.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):647-9 [15612025.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2507-16 [15856474.001]
  • (PMID = 20737151.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M: Pathological and molecular features of adrenocortical carcinoma: an update. J Clin Pathol; 2008 Jul;61(7):787-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological and molecular features of adrenocortical carcinoma: an update.
  • The pathological diagnosis of adrenocortical carcinoma (ACC), which is based on gross and microscopic criteria, is subjective.
  • The classification of oncocytic and paediatric adrenocortical tumours is even more challenging, as not all of the above morphological parameters are predictors of malignancy in these tumour types.
  • Genetic and epigenetic alterations of p53, IGF-2 and molecules involved in cancer cell invasive properties seem the most promising.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology
  • [MeSH-minor] Algorithms. Biomarkers, Tumor / metabolism. Chromosome Aberrations. Diagnosis, Differential. Humans. Immunophenotyping. Neoplastic Syndromes, Hereditary / genetics

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430754.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 75
  •  go-up   go-down


24. Meyer A, Behrend M: State of the art management of adrenal masses--"how to do it?". Eur J Med Res; 2006 Sep 29;11(9):397-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State of the art management of adrenal masses--"how to do it?".
  • By the frequent use of computed tomography or ultrasound the detection of incidentally found adrenal tumours has become a common problem.
  • Most incidentally-found adrenal tumours are benign non-functioning cortical adenomas.
  • But benign functioning tumours producing aldosterone, cortisol or catecholamines, adrenocortical carcinoma or adrenal gland metastasis can also be found.
  • Surgical therapy is always indicated in case of hormonal overproduction or in case of suspected adrenocortical carcinoma; in all other cases the correct and adequate therapeutic approach is still under debate and a controversial topic of discussion.
  • This review deals with the different forms of adrenal tumours regarding the optimal diagnostic and therapeutic approach to give physicians an easy-to-follow guideline.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101464.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


25. Breen MS, Breen M, Terasaki N, Yamazaki M, Conolly RB: Computational model of steroidogenesis in human H295R cells to predict biochemical response to endocrine-active chemicals: model development for metyrapone. Environ Health Perspect; 2010 Feb;118(2):265-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An in vitro steroidogenesis assay using the human adrenocortical carcinoma cell line H295R is being evaluated as a possible screening assay to detect and assess the impact of endocrine-active chemicals (EACs) capable of altering steroid biosynthesis.
  • OBJECTIVES: The goal of this study was to develop a mechanistic computational model of the metabolic network of adrenal steroidogenesis to estimate the synthesis and secretion of adrenal steroids in human H295R cells and their biochemical response to steroidogenesis-disrupting EAC.
  • METHODS: We developed a deterministic model that describes the biosynthetic pathways for the conversion of cholesterol to adrenal steroids and the kinetics for enzyme inhibition by metryrapone (MET), a model EAC.
  • A sensitivity analysis indicated the parameter uncertainties and identified transport and metabolic processes that most influenced the concentrations of primary adrenal steroids, aldosterone and cortisol.
  • [MeSH-major] Adrenal Glands / drug effects. Endocrine Disruptors / pharmacology. Metyrapone / pharmacology. Steroids / metabolism
  • [MeSH-minor] Cell Line, Tumor. Computational Biology / methods. Humans. Models, Theoretical

  • Hazardous Substances Data Bank. METYRAPONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Phys Lipids. 2000 Mar;105(1):9-29 [10727111.001]
  • [Cites] Am J Physiol. 1980 Jul;239(1):R184-95 [7396035.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Dec 31;75(4-5):229-36 [11282276.001]
  • [Cites] Toxicol Appl Pharmacol. 2002 Jul 1;182(1):44-54 [12127262.001]
  • [Cites] Neuro Endocrinol Lett. 2002 Jul;23 Suppl 2:43-7 [12163847.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):891-8 [12370264.001]
  • [Cites] J Appl Toxicol. 2003 Mar-Apr;23(2):81-7 [12666151.001]
  • [Cites] Toxicol Sci. 2003 Aug;74(2):245-52 [12730617.001]
  • [Cites] Toxicol Sci. 2004 Jan;77(1):151-7 [14600281.001]
  • [Cites] Science. 1986 Apr 4;232(4746):34-47 [3513311.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):295-318 [3061784.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5488-96 [2386954.001]
  • [Cites] Mol Endocrinol. 1993 Mar;7(3):423-33 [8387159.001]
  • [Cites] Mol Cell Endocrinol. 1994 Apr;100(1-2):45-50 [8056157.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21604-13 [8702948.001]
  • [Cites] J Endocrinol. 1997 Feb;152(2):159-66 [9071972.001]
  • [Cites] Environ Health Perspect. 1998 Apr;106 Suppl 2:577-82 [9599705.001]
  • [Cites] J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):131-41 [10418987.001]
  • [Cites] Endocr Rev. 2004 Dec;25(6):947-70 [15583024.001]
  • [Cites] Reprod Toxicol. 2005 Jan-Feb;19(3):395-409 [15686873.001]
  • [Cites] Endocrinology. 2005 Jun;146(6):2531-8 [15774561.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):259-70 [15985365.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S25-32 [16690802.001]
  • [Cites] Environ Health Perspect. 2006 Apr;114 Suppl 1:106-14 [16818255.001]
  • [Cites] Toxicol Sci. 2006 Nov;94(1):3-21 [16807284.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:129-57 [16753029.001]
  • [Cites] Ecotoxicol Environ Saf. 2006 Nov;65(3):293-305 [16935330.001]
  • [Cites] J Appl Toxicol. 2006 Nov-Dec;26(6):484-92 [17080404.001]
  • [Cites] J Appl Toxicol. 2007 Mar-Apr;27(2):103-15 [17265431.001]
  • [Cites] Ann Biomed Eng. 2007 Jun;35(6):970-81 [17436109.001]
  • [Cites] Ecotoxicol Environ Saf. 2007 Sep;68(1):20-32 [17449096.001]
  • [Cites] Anal Bioanal Chem. 2008 Jan;390(1):287-91 [17957359.001]
  • [Cites] J Appl Toxicol. 2008 Nov;28(8):1045-53 [18626888.001]
  • [Cites] Environ Toxicol. 2009 Oct;24(5):513-21 [19161236.001]
  • [ErratumIn] Environ Health Perspect. 2011 Jan;119(1):A11
  • (PMID = 20123619.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endocrine Disruptors; 0 / Steroids; ZS9KD92H6V / Metyrapone
  • [Other-IDs] NLM/ PMC2831928
  •  go-up   go-down


26. Oskarsson A, Ullerås E, Plant KE, Hinson JP, Goldfarb PS: Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro. J Appl Toxicol; 2006 Nov-Dec;26(6):484-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro.
  • The focus on the refinement, reduction and replacement of animal use in toxicity testing requires the development of cell-based systems that mimic the effects of xenobiotics in human tissues.
  • The human adrenocortical carcinoma cell line, H295R, has been proposed as a model for studies on adrenal steroidogenesis and its disruption.
  • In this study, expression profiles for nine adrenal steroidogenic genes were characterized in H295R cells using real-time RT-PCR.
  • The transcript profile from H295R cells in the presence and absence of forskolin was compared with the transcript profile from human adrenal glands.
  • The gene expression pattern observed in the forskolin-treated H295R cells was more similar to that in the human adrenal gland, than the expression pattern in untreated cells.
  • To examine H295R cells as a possible in vitro system for the assessment of adrenal disruption using molecular endpoints, the insecticide lindane (gamma-hexachlorocyclohexane) was used.
  • In vivo, lindane has been shown to inhibit testicular, ovarian and adrenal steroidogenesis.
  • It was demonstrated that lindane reduced cortisol secretion, downregulated the expression of a subset of the genes encoding steroidogenic enzymes and repressed transcriptional activation of the steroidogenic acute regulatory protein (StAR) gene promoter.
  • Thus the H295R cell line provides a good in vitro system for the analysis of the human adrenal steroidogenic pathway at the level of hormone production and gene expression.
  • This in vitro test can be used for the rapid detection of adrenal endocrine disruption and as a tool for mechanistic studies.
  • [MeSH-major] Adrenal Cortex / drug effects. Adrenal Cortex Hormones / biosynthesis. Gene Expression Regulation / drug effects. Insecticides / toxicity. Lindane / toxicity
  • [MeSH-minor] Cell Proliferation / drug effects. Cells, Cultured. Colforsin / pharmacology. Humans. Hydrocortisone / secretion. Phosphoproteins / genetics. Promoter Regions, Genetic. Steroid 11-beta-Hydroxylase / genetics. Sulfotransferases / genetics

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. LINDANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 John Wiley & Sons, Ltd.
  • (PMID = 17080404.001).
  • [ISSN] 0260-437X
  • [Journal-full-title] Journal of applied toxicology : JAT
  • [ISO-abbreviation] J Appl Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Insecticides; 0 / Phosphoproteins; 0 / steroidogenic acute regulatory protein; 1F7A44V6OU / Colforsin; 59NEE7PCAB / Lindane; EC 1.14.15.4 / Steroid 11-beta-Hydroxylase; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.2 / alcohol sulfotransferase; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


27. Waalkes MP, Liu J, Diwan BA: Transplacental arsenic carcinogenesis in mice. Toxicol Appl Pharmacol; 2007 Aug 1;222(3):271-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In C3H mice, two separate studies show male offspring exposed to arsenic in utero developed liver carcinoma and adrenal cortical adenoma in a dose-related fashion during adulthood.
  • Prenatally exposed female C3H offspring show dose-related increases in ovarian tumors and lung carcinoma and in proliferative lesions (tumors plus preneoplastic hyperplasia) of the uterus and oviduct.
  • Male CD1 mice treated with arsenic in utero develop tumors of the liver and adrenal and renal hyperplasia while females develop tumors of urogenital system, ovary, uterus and adrenal and hyperplasia of the oviduct.
  • Additional postnatal treatment with diethylstilbestrol or tamoxifen after prenatal arsenic in CD1 mice induces urinary bladder transitional cell proliferative lesions, including carcinoma and papilloma, and enhances the carcinogenic response in the liver of both sexes.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Carcinog. 1997 Aug;19(4):236-42 [9290700.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):209-18 [9219559.001]
  • [Cites] Carcinogenesis. 1997 Dec;18(12):2293-8 [9450472.001]
  • [Cites] Toxicol Sci. 1998 Aug;44(2):185-90 [9742656.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1489-97 [9788961.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1775-85 [9846968.001]
  • [Cites] Pediatr Nephrol. 1999 Feb;13(2):171-8 [10229008.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1873-6 [10469637.001]
  • [Cites] Exp Cell Res. 2005 Jan 1;302(1):96-107 [15541729.001]
  • [Cites] Chem Res Toxicol. 2004 Dec;17(12):1733-42 [15606151.001]
  • [Cites] Toxicol Sci. 2005 Feb;83(2):237-45 [15537745.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;84:269-477 [15645578.001]
  • [Cites] Cancer Lett. 2005 Jun 1;223(1):27-35 [15890234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8644-9 [15937110.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2179-86 [16014701.001]
  • [Cites] Oncogene. 2005 Dec 15;24(56):8217-28 [16355251.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1337-45 [16452187.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94 [10852857.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):404-11 [16507464.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Jun 15;213(3):216-23 [16368122.001]
  • [Cites] Toxicology. 2006 Jul 5;224(1-2):147-55 [16753250.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1293-6 [16882542.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Sep 15;215(3):295-305 [16712894.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Jul 1;166(1):24-35 [10873715.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):135-45 [10963625.001]
  • [Cites] Toxicol Sci. 2001 Jan;59(1):68-74 [11134545.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5389-95 [11454681.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Oct 1;176(1):64-71 [11578149.001]
  • [Cites] Environ Health Perspect. 2002 Apr;110(4):331-6 [11940449.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1387-97 [12151359.001]
  • [Cites] Chem Res Toxicol. 2002 Sep;15(9):1150-7 [12230408.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:767-71 [12426129.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):389-94 [12676588.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Dec 15;193(3):309-34 [14678742.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):133-41 [14514661.001]
  • [Cites] Toxicol Sci. 2004 Feb;77(2):249-57 [14691202.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Environ Health Perspect. 2004 Apr;112(5):599-603 [15064167.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):327-35 [15276412.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1779-86 [15073043.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):142-50 [15313586.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):162-74 [15313588.001]
  • [Cites] Cancer Res. 1975 Mar;35(3):766-80 [1167809.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 Nov 17;376(2):117-32 [145710.001]
  • [Cites] Carcinogenesis. 1981;2(11):1087-94 [6797749.001]
  • [Cites] Teratology. 1987 Feb;35(1):19-25 [3563933.001]
  • [Cites] Toxicol Pathol. 1988;16(3):340-9 [3194656.001]
  • [Cites] Cancer Lett. 1993 Feb;68(2-3):193-8 [8443792.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3874-6 [8358711.001]
  • [Cites] Pathology. 1994 Apr;26(2):154-60 [7522317.001]
  • [Cites] Carcinogenesis. 1995 Aug;16(8):1993-6 [7634431.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:203-32 [8725388.001]
  • [Cites] Carcinogenesis. 1997 Oct;18(10):2009-14 [9364013.001]
  • (PMID = 17306315.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z01 BC005488-21; United States / Intramural NIH HHS / / Z99 ES999999; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Arsenicals; 0 / Carcinogens; 0 / Estrogens; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS28781; NLM/ PMC1995036
  •  go-up   go-down


28. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A: Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab; 2009 Apr;23(2):233-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adrenal incidentaloma.
  • Clinically inapparent adrenal masses, or adrenal incidentalomas, are discovered inadvertently in the course of work-up or treatment of unrelated disorders.
  • Cortical adenoma is the most frequent tumour detected incidentally, but adrenocortical cancer, phaeochromocytoma and metastasis are not rare.
  • Two critical questions should be answered before trying to outline the management of adrenal incidentaloma:.
  • (1) identify either primary (adrenocortical cancer) or secondary (adrenal metastasis) malignancy;.
  • Radiological evaluation is the key to the differential diagnosis of benign and malignant tumours.
  • Endocrine testing is necessary to exclude phaeochromocytoma in all patients with an adrenal incidentaloma because this tumour may remain undiagnosed after imaging studies.
  • The management of clinically inapparent adrenal adenomas may vary depending whether or not they are functioning.
  • Also the management of this condition is largely empirical, and data are insufficient to indicate the superiority of a surgical or non-surgical approach to managing patients with subclinical Cushing's syndrome.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / drug therapy. Adenoma / therapy. Animals. Humans. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500766.001).
  • [ISSN] 1878-1594
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 46
  •  go-up   go-down


29. Thompson MA, Habra MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG, Rodriguez MA: Primary adrenal natural killer/T-cell nasal type lymphoma: first case report in adults. Am J Hematol; 2007 Apr;82(4):299-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adrenal natural killer/T-cell nasal type lymphoma: first case report in adults.
  • We report the first case of a primary adrenal natural killer (NK)/T-cell nasal type lymphoma in adults.
  • The patient presented with an enlarging left adrenal mass and the initial concern was for adrenocortical carcinoma.
  • Surgical resection revealed NK/T-cell lymphoma.
  • Rapid recurrence in the contralateral adrenal gland was treated with a single cycle of chemotherapy before he died due to infectious complications and progressive disease.
  • This case demonstrates the aggressive presentation of a novel subset of primary adrenal lymphoma that should be considered in the differential diagnosis of a rapidly enlarging adrenal mass.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Killer Cells, Natural / pathology. Lymphocyte Subsets / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Male. RNA, Viral

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094095.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral
  •  go-up   go-down


30. Ferreira U, Nardi Pedro R, Matheus WE, Prudente A, Mendonça Borges G, Rodrigues Netto N Jr: Open surgical treatment of right-sided adrenal carcinomas &gt;15 cm. Urol Int; 2007;78(1):46-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Open surgical treatment of right-sided adrenal carcinomas >15 cm.
  • INTRODUCTION: Adrenal carcinomas are rare and are associated with a very poor prognosis.
  • The incidence is estimated to be 1 in 1.7 million which represents 0.02% of all cancers and 0.2% of all cancer mortality.
  • The purpose of this paper is to present a single-institution experience in excising right-sided giant adrenal carcinomas, discussing the difficulties and the usage of special surgical devices to facilitate the procedure.
  • PATIENTS AND METHODS: During June 2001 to June 2003, 18 patients with right-sided adrenal tumors were treated at the State University of Campinas Hospital--UNICAMP.
  • RESULTS: Adrenal cortical carcinoma was the histological diagnosis according to the Weiss criteria; no positive surgical margin was detected, even in those patients with invasion of the hepatic capsule.
  • [MeSH-major] Adrenalectomy / methods. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192732.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


31. Dichtchekenian V, de Bragança Pereira CA, Kuperman H, Della Manna T, Damiani D, Ferreira Alves VA, Filho AL, Setian N: Adrenocortical carcinoma: prognostic indices based on clinical and immunohistochemical markers. J Pediatr Endocrinol Metab; 2005 Apr;18(4):347-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: prognostic indices based on clinical and immunohistochemical markers.
  • Adrenocortical carcinoma is a rare condition with an unpredictable prognosis as a rule.
  • Y = 1 when chronological age (CA) >33 mo, Y = 0 when CA < or =33 mo; L = 1 for right sided tumor and L = 0 for left sided tumor; H = 1 in presence of hypertension and H = 0 for normal blood pressure; T = length of disease in months; W = weight of tumor (g); O = 1 in the absence of p53 protein and O = 0 in the presence of p53.
  • [MeSH-major] Adrenal Cortex Neoplasms / physiopathology. Adrenocortical Carcinoma / physiopathology. Biomarkers, Tumor / metabolism. Models, Biological

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844468.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L: Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer; 2005 Sep;12(3):657-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
  • To investigate the activity of etoposide, doxorubicin, and cisplatin plus mitotane in the management of advanced adrenocortical carcinoma (ACC) patients, 72 patients with measurable disease not amenable to radical surgery were enrolled in a prospective, multicenter phase II trial.
  • Radical surgical resection of residual disease after chemotherapy was performed in 10 patients.
  • The overall survival of patients attaining a disease free status (clinical complete responders+radically resected) was significantly higher than that of patients with partial response or no response (P<0.002).
  • Surgical resection of residual disease subsequent to chemotherapy leads to a more favourable outcome.
  • The natural history of the disease is significantly influenced by the secretory status of the tumor.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Injections, Intravenous. Male. Middle Aged. Mitotane / administration & dosage. Neoplasm Staging. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172198.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 78E4J5IB5J / Mitotane; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Sèbe P, Rigaud J, Avancès C, Brunaud L, Caillard C, Camparo P, Carnaille B, Culine S, Durand X, Mathonnet M, Mirallie E, Soulié M, Oncology Committee of the French Association of Urology (CCAFU): [Malignant tumors of the adrenal: contribution to the repository CCAFU INCa]. Prog Urol; 2010 Nov;20 Suppl 4:S310-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant tumors of the adrenal: contribution to the repository CCAFU INCa].
  • [Transliterated title] Tumeurs malignes de la surrénale: Contribution du CCAFU au référentiel INCa.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy
  • [MeSH-minor] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / therapy. Adrenalectomy. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / therapy. Chemotherapy, Adjuvant. Follow-Up Studies. France. Humans. Neoadjuvant Therapy / methods. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129649.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] France
  •  go-up   go-down


34. Lahera Vargas M, da Costa CV: [Prevalence, etiology and clinical findings of Cushing's syndrome]. Endocrinol Nutr; 2009 Jan;56(1):32-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prevalencia, etiología y cuadro clínico del síndrome de Cushing.
  • Cushing's disease is the most frequent cause of endogenous Cushing's syndrome, which is 5 or 6 times more frequent than adrenal Cushing's syndrome, with an incidence of between 1.2 and 2.4 cases per million inhabitants per year.
  • Cushing's disease is 3-8 times higher in women than in men.
  • The frequency of adrenal tumors is 3 times higher in women, while that of Cushing's syndrome due to adrenal tumors is 3-5 times higher.
  • Age at diagnosis of Cushing's syndrome varies according to the etiology.
  • Most cases of Cushing's disease are due to a pituitary adenoma, although the tumor may not be visible on the available imaging techniques.
  • ACTH-independent Cushing's syndrome is found in 20% of cases and is most frequently due to adenomas (10%) or adrenal carcinomas (8).
  • Both familial and sporadic forms exist: the familial form, or Carney complex, and ACTH-independent bilateral macronodular hyperplasia, in which the size of the adrenal glands is considerably enlarged.
  • [MeSH-minor] ACTH Syndrome, Ectopic / complications. Adenoma / complications. Adenoma / secretion. Adrenal Cortex / pathology. Adrenal Cortex Neoplasms / complications. Adrenal Cortex Neoplasms / secretion. Carcinoma / complications. Carcinoma / secretion. Cardiovascular Diseases / epidemiology. Diabetes Mellitus / epidemiology. Female. Glucocorticoids / adverse effects. Humans. Hydrocortisone / secretion. Hyperplasia. Incidence. Male. Phenotype. Pituitary ACTH Hypersecretion / complications. Pituitary Neoplasms / complications. Pituitary Neoplasms / secretion. Prevalence. Risk

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627706.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Glucocorticoids; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 59
  •  go-up   go-down


35. Gasilionis V, Ersahin C, Gabram S, Bova D, Branch J, Rajan P: Adrenal cortical carcinoma metastatic to the breast. J Clin Pathol; 2006 May;59(5):546-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal cortical carcinoma metastatic to the breast.
  • A 56 year old woman was diagnosed with adrenal cortical carcinoma in May 2003, for which she underwent left radical adrenalectomy.
  • A diagnosis of metastatic adrenal cortical carcinoma was made on core biopsy.
  • Subsequently, the patient underwent a lumpectomy of the mass, which confirmed the diagnosis.
  • To our knowledge, this is the first case report of adrenal cortical carcinoma metastatic to the breast.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Breast Neoplasms / secondary. Carcinoma / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1982 Jul;144(2):309-12 [7089284.001]
  • [Cites] J Clin Pathol. 1988 Feb;41(2):171-2 [2832451.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Jul;89(4):251-6 [7315321.001]
  • [Cites] J Pediatr Surg. 1994 Jan;29(1):48-51 [8120761.001]
  • [Cites] J Am Coll Surg. 1994 Jul;179(1):49-53 [8019724.001]
  • [Cites] J Surg Oncol. 1991 Oct;48(2):112-6 [1921396.001]
  • (PMID = 16644887.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860300
  •  go-up   go-down


36. Karakas Z, Tugcu D, Unuvar A, Atay D, Akcay A, Gedik H, Kayserili H, Dogan O, Anak S, Devecioglu O: Li-Fraumeni syndrome in a Turkish family. Pediatr Hematol Oncol; 2010 May;27(4):297-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adrenocortical carcinoma (ACC) association with acute leukemia is unusual in childhood, even in LFS.
  • The authors here present a family with pR337P mutation in TP53 gene who had a child with acute lymphoblastic leukemia (ALL) and associated adrenocortical carcinoma as a case 1 and his cousin with brain tumor as a case 2.
  • A hereditary TP53 mutation supported the diagnosis of LFS in this family.
  • The availability of a reliable molecular marker to detect the R337P TP53 mutation allows the rapid identification of carriers in families that have a child with ACC.
  • [MeSH-major] Adrenocortical Carcinoma / genetics. Brain Neoplasms / genetics. Li-Fraumeni Syndrome / genetics. Mutation, Missense. Neoplasms, Second Primary / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426520.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


37. Dundr P, Povýsil C, Zelinka T, Tvrdík D, Ciprová V, Novák K: Adrenocortical adenoma with rhabdoid features. Pathol Res Pract; 2006;202(3):177-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical adenoma with rhabdoid features.
  • We report a case of an aldosterone producing adrenocortical adenoma with rhabdoid features in a 16-year-old girl.
  • Rhabdoid features have been described in many tumors of variable histogenesis; however, to the best of our knowledge, the presence of rhabdoid phenotype has never been described in either adrenocortical adenoma or carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / pathology. Rhabdoid Tumor / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16448785.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 4964P6T9RB / Aldosterone
  •  go-up   go-down


38. Grubbs E, Lee JE: Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer; 2009 Dec 15;115(24):5847; author reply 5848
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification.
  • [MeSH-major] Adrenocortical Carcinoma / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • (PMID = 19827149.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


39. Roman S: Adrenocortical carcinoma. Curr Opin Oncol; 2006 Jan;18(1):36-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma.
  • PURPOSE OF REVIEW: Adrenocortical carcinoma is a rare malignancy, accounting for 0.02% of all annual cancers reported.
  • Given the generally advanced stage at diagnosis, the overall 5-year survival remains poor, varying between 20 and 45%.
  • RECENT FINDINGS: Recent studies focusing on the tumorigenesis of adrenocortical carcinoma have focused on onco-developmental genes present in the fetal adrenal cortex, as well as local adrenal paracrine and autocrine effects of cellular peptides.
  • SUMMARY: Pre-operative diagnostic advances in positron emission scanning are emerging as promising modalities for confirmation of malignancy of indeterminate adrenal masses.
  • No significant advances in the treatment of adrenocortical carcinoma have been developed.
  • Surgery remains the mainstay for primary and recurrent disease, including select patients with isolated liver metastases.
  • Mitotane has remained the preferred adjuvant treatment agent, showing modest effect in patients with unresectable, residual or metastatic disease.
  • [MeSH-major] Adrenal Cortex Neoplasms. Adrenocortical Carcinoma

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357562.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Vascular Endothelial Growth Factor A; 104625-48-1 / Activins; 57285-09-3 / Inhibins; 78E4J5IB5J / Mitotane
  • [Number-of-references] 38
  •  go-up   go-down


40. Nishikawa T, Saito J, Omura M: [Medical treatment for Cushing's syndrome]. Nihon Rinsho; 2008 Jan;66(1):186-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is well known that the development of the microvascular disease of various organs such as the heart and kidney, in patients with diabetes mellitus, hyperlipidemia and hypertension of which disorders are frequently associated with Cushing's syndrome.
  • Thus, we should treat Cushing's syndrome as soon as possible, since many complications, including cardiovascular diseases and infections, will soon occur when the definite diagnosis is delayed.
  • Medical adrenalectomy is achieved by using with mitotane which is usually used for adrenocortical cancer.
  • We commonly treat the patients with Cushing's syndrome due to adrenal tumor and pituitary or ectopic ACTH producing tumor by using metyrapone which mainly inhibits 11-hydroxylase.
  • Metyrapone is also recommended to treat the patients who are not well differentiated Cushing's disease from ectopic ACTH syndrome.
  • Replacement therapy with hydrocortisone should be considered if adrenal failure will occur during treatment with those drugs.

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. AMINOGLUTETHIMIDE .
  • Hazardous Substances Data Bank. METYRAPONE .
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186263.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0O54ZQ14I9 / Aminoglutethimide; EC 1.14.15.4 / Steroid 11-beta-Hydroxylase; R9400W927I / Ketoconazole; ZS9KD92H6V / Metyrapone
  • [Number-of-references] 6
  •  go-up   go-down


41. Hofland J, Timmerman MA, de Herder WW, van Schaik RH, de Krijger RR, de Jong FH: Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms. Clin Endocrinol (Oxf); 2006 Dec;65(6):792-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.
  • OBJECTIVE: The growth and differentiation factors activin and inhibin can affect tumour formation and steroid production in the adrenal cortex.
  • Expression of these activin-related mRNAs was measured in different types of adrenocortical tissues and tumours to study the relationship with tumorigenesis.
  • DESIGN: Quantitative expression of activin-related mRNAs was investigated in patient adrenocortical samples.
  • PATIENTS: Twenty-eight human adrenocortical samples from normal and hyperplastic adrenals and from adrenocortical adenomas and carcinomas were collected after surgery for study purposes.
  • MEASUREMENTS: Using quantitative reverse transcription polymerase chain reaction (RT-PCR), we investigated the expression of inhibin alpha-, betaA- and betaB-subunits, follistatin, betaglycan, ActRIIA, ActRIIB and Alk-4 in the adrenocortical tissues.
  • RESULTS: All genes studied were expressed in all tissues, with the exception of the inhibin alpha-subunit in one hyperplastic adrenal and three adrenocortical carcinomas.
  • Expression of inhibin betaA-subunit, follistatin, betaglycan, ActRIIA, ActRIIB and CYP17 differed between nontumorous adrenals and carcinomas.
  • We conclude that the expression of activin and inhibin subunits, receptors and binding proteins is affected by tumour formation in the adrenal gland and may play a role in tumorigenesis.
  • [MeSH-major] Activins / metabolism. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Adenoma / metabolism. Adrenocortical Carcinoma / metabolism. Inhibins / metabolism
  • [MeSH-minor] Activin Receptors, Type II / genetics. Activin Receptors, Type II / metabolism. Adrenal Cortex / metabolism. Adrenal Cortex / pathology. Adult. Carrier Proteins / genetics. Carrier Proteins / metabolism. Female. Follistatin / genetics. Follistatin / metabolism. Gene Expression. Humans. Hyperplasia. Inhibin-beta Subunits / genetics. Inhibin-beta Subunits / metabolism. Male. Middle Aged. Proteoglycans / genetics. Proteoglycans / metabolism. Receptors, Transforming Growth Factor beta / genetics. Receptors, Transforming Growth Factor beta / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Steroid 17-alpha-Hydroxylase / genetics. Steroid 17-alpha-Hydroxylase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121532.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Follistatin; 0 / Proteoglycans; 0 / Receptors, Transforming Growth Factor beta; 0 / inhibin beta A subunit; 0 / inhibin-alpha subunit; 104625-48-1 / Activins; 145170-29-2 / betaglycan; 57285-09-3 / Inhibins; 93443-12-0 / Inhibin-beta Subunits; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


42. Luconi M, Mangoni M, Gelmini S, Poli G, Nesi G, Francalanci M, Pratesi N, Cantini G, Lombardi A, Pepi M, Ercolino T, Serio M, Orlando C, Mannelli M: Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr Relat Cancer; 2010 Mar;17(1):169-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model.
  • Adrenocortical carcinoma (ACC) is a rare aggressive tumor with a poor prognosis.
  • The lack of a specific and effective medical treatment is due to the poor knowledge of the mechanisms underlying tumor growth.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Carcinoma / pathology. Cell Proliferation / drug effects. Thiazolidinediones / pharmacology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Hypoglycemic Agents / pharmacology. Hypoglycemic Agents / therapeutic use. Mice. Mice, Nude. Tumor Burden / drug effects. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955217.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypoglycemic Agents; 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone
  •  go-up   go-down


43. Sun XY, Li XG, Gao H, Zhou XQ, Zheng HW: [Renal clear cell carcinoma associated with pelvis hemangioma and adrenal cortical adenoma: report of a case]. Zhonghua Bing Li Xue Za Zhi; 2007 May;36(5):352-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal clear cell carcinoma associated with pelvis hemangioma and adrenal cortical adenoma: report of a case].
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / pathology. Carcinoma, Renal Cell / pathology. Hemangioma / pathology. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Pelvic Neoplasms / pathology


44. Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner S, Saeger W, Bertherat J, Allolio B, Fassnacht M: High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab; 2010 Oct;95(10):E161-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
  • CONTEXT: No immunohistochemical marker has been established to reliably differentiate adrenocortical tumors from other adrenal masses.
  • We hypothesized that expression of steroidogenic factor-1 (SF-1), a transcription factor involved in adrenal development, is of value for the differential diagnosis of adrenal masses and predicts prognosis in adrenocortical carcinoma (ACC).
  • PATIENTS AND METHODS: SF-1 protein expression was assessed by immunohistochemistry on tissue samples from 167 ACC, 52 adrenocortical adenomas (ACA), six normal adrenal glands, six normal ovaries and 73 neoplastic nonsteroidogenic tissues.
  • In addition, SF-1 mRNA expression was present in all 91 analyzed adrenocortical tumors.
  • CONCLUSION: SF-1 is a highly valuable immunohistochemical marker to determine the adrenocortical origin of an adrenal mass with high sensitivity and specificity.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Adrenocortical Carcinoma / diagnosis. Steroidogenic Factor 1 / genetics
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cohort Studies. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660055.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NR5A1 protein, human; 0 / Steroidogenic Factor 1
  •  go-up   go-down


45. Coli A, Di Giorgio A, Castri F, Destito C, Marin AW, Bigotti G: Sarcomatoid carcinoma of the adrenal gland: A case report and review of literature. Pathol Res Pract; 2010 Jan 15;206(1):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma of the adrenal gland: A case report and review of literature.
  • Reports about adrenocortical carcinomas (AC) mixed with sarcomatous areas are very rare.
  • Herein, we report a case of sarcomatoid carcinoma of the adrenal gland in a 75-year-old woman who presented with left abdominal pain of one month's standing.
  • The results of abdominal ultrasonography and computed tomography (CT) showed the presence of a large heterogeneous adrenal mass.
  • Histologically, the neoplasm showed areas of adrenocortical carcinoma and areas of sarcomatoid spindle cell proliferation.
  • Twelve months after removal of the primary tumor, the patient died of her disease.
  • To the best of our knowledge, only seven cases of adrenal sarcomatoid carcinoma have been reported in the medical literature.
  • We review the reported cases according to the 2004 classification of the World Health Organization (WHO) of lung tumors, and highlight the histogenesis, diagnosis, and clinical course of this very aggressive tumor.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Carcinosarcoma / secondary. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19369012.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 16
  •  go-up   go-down


46. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M, German Adrenocortical Carcinoma Registry Group: Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol; 2010 Oct;58(4):609-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients.
  • BACKGROUND: The role of laparoscopic adrenalectomy in the treatment of patients with adrenocortical carcinoma (ACC) is controversial.
  • OBJECTIVE: Our aim was to compare oncologic outcome in patients with ACC who underwent either open adrenalectomy (OA) or laparoscopic adrenalectomy (LA) for localised disease.
  • INTERVENTION: Patients were stratified into two groups according to the surgical procedure (LA or OA).
  • For comparison, we used both a matched pairs approach by selecting for each patient from the LA group (n=35) one corresponding patient from the OA group (n=117) and multivariate analysis in all 152 patients.
  • MEASUREMENTS: Disease-specific survival was chosen as the predefined primary end point.
  • Secondary end points were recurrence-free survival, frequency of tumour capsule violation and postoperative peritoneal carcinomatosis, and incidence and reasons for conversion from LA to OA.
  • RESULTS AND LIMITATIONS: LA and OA did not differ with regard to the primary end point using either the matched pairs approach (hazard ratio [HR] for death: 0.79; 95% confidence interval [CI], 0.36-1.72; p=0.55) or multivariate analysis (HR for death: 0.98; 95% CI, 0.51-1.92; p=0.92).
  • Similarly, adjusted recurrence-free survival was not different between LA and OA (HR: 0.91; 95% CI, 0.56-1.47; p=0.69).
  • In 12 of 35 patients of the LA group, surgery was converted to open surgery with no impact on the clinical outcome.
  • CONCLUSIONS: For localised ACC with a diameter of < or =10 cm, LA by an experienced surgeon is not inferior to OA with regard to oncologic outcome.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Laparoscopy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur Urol. 2010 Dec;58(6):e53; author reply e54 [20864252.001]
  • (PMID = 20580485.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


47. Goldschneider KR, Racadio JM, Weidner NJ: Celiac plexus blockade in children using a three-dimensional fluoroscopic reconstruction technique: case reports. Reg Anesth Pain Med; 2007 Nov-Dec;32(6):510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One carried the diagnosis of chronic pancreatitis, one abdominal pain and gastrointestinal dysmotility, the other adrenocortical carcinoma.
  • [MeSH-minor] Adrenal Cortex Neoplasms / complications. Adult. Carcinoma / complications. Child. Child, Preschool. Cystic Fibrosis / complications. Fatal Outcome. Gastrointestinal Motility / drug effects. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Mitochondrial Diseases / complications. Pain / drug therapy. Pain / etiology. Palliative Care. Pancreatitis / complications

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035298.001).
  • [ISSN] 1098-7339
  • [Journal-full-title] Regional anesthesia and pain medicine
  • [ISO-abbreviation] Reg Anesth Pain Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Takahashi K, Shoji I, Shibasaki A, Kato I, Hiraishi K, Yamamoto H, Kaneko K, Murakami O, Morimoto R, Satoh F, Ito S, Totsune K: Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors. J Mol Neurosci; 2010 May;41(1):138-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors.
  • Kisspeptins have also been reported to stimulate the aldosterone secretion from the adrenal cortex.
  • However, the expression of kisspeptins in human adrenal glands and adrenal tumors has not been clarified yet.
  • We, therefore, studied the presence of kisspeptin-like immunoreactivity (LI) in human adrenal glands and adrenal tumors (adrenocortical adenomas, adrenocortical carcinomas, and pheochromocytomas) by radioimmunoassay and immunocytochemistry.
  • Kisspeptin-LI was detected in all the tissues examined; normal portions of adrenal glands (3.0 +/- 2.3 pmol/g wet weight, n = 21, mean +/- SD), aldosterone-producing adenomas (4.6 +/- 3.3 pmol/g wet weight, n = 10), cortisol-producing adenomas (2.7 +/- 1.4 pmol/g wet weight, n = 14), adrenocortical carcinomas (1.7 +/- 0.2 pmol/g wet weight, n = 4), and pheochromocytomas (1.8 +/- 0.8 pmol/g wet weight, n = 6).
  • Immunocytochemistry showed positive kisspeptin-immunostaining in normal adrenal glands, with stronger immunostaining found in the medulla.
  • Furthermore, positive kisspeptin-immunostaining was found in all types of adrenal tumors examined; adrenocortical adenomas, adrenocortical carcinomas, and pheochromocytomas.
  • The intensity of kisspeptin-immunostaining in these adrenal tumors was, however, not so strong as that in normal adrenal medulla.
  • The present study has shown for the first time the presence of kisspeptin-LI in adrenal glands and adrenal tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenal Glands / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetologia. 2009 May;52(5):855-62 [19221709.001]
  • [Cites] N Engl J Med. 2003 Oct 23;349(17):1614-27 [14573733.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1897-903 [15070962.001]
  • [Cites] Peptides. 1992 Jan-Feb;13(1):121-3 [1535705.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Aug;76(8):4079-83 [386355.001]
  • [Cites] Peptides. 2003 Feb;24(2):301-6 [12668216.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4671-8 [15914529.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34631-6 [11457843.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1319-28 [15020672.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 4;88(23):1731-7 [8944003.001]
  • [Cites] Reprod Sci. 2007 Dec;14(8):836-45 [18089602.001]
  • [Cites] Peptides. 2008 May;29(5):873-80 [17686550.001]
  • [Cites] Endocr J. 2008 Mar;55(1):49-55 [18187873.001]
  • [Cites] Neurosci Lett. 1996 Jan 26;203(3):207-10 [8742029.001]
  • [Cites] Endocrinology. 2007 Jan;148(1):140-7 [17023533.001]
  • [Cites] Peptides. 2000 Feb;21(2):251-6 [10764953.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28969-75 [11387329.001]
  • [Cites] Diabetologia. 2006 Sep;49(9):2131-5 [16826407.001]
  • [Cites] Nature. 2001 May 31;411(6837):613-7 [11385580.001]
  • [Cites] Endocrinology. 2004 Sep;145(9):4073-7 [15217982.001]
  • [Cites] Lancet. 1983 Sep 3;2(8349):540-2 [6136694.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6609-15 [16174713.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4565-74 [15242985.001]
  • [Cites] J Neuroendocrinol. 2009 Mar;21(4):299-304 [19210293.001]
  • [Cites] J Endocrinol. 2008 Jul;198(1):175-83 [18460550.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 19898965.001).
  • [ISSN] 1559-1166
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KISS1 protein, human; 0 / Kisspeptins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


49. Mahe E, El-Shinnawy I: A "tumour trifecta:" myelolipomata arising within an adrenocortical adenoma ipsilateral to a synchronous clear cell renal cell carcinoma. Malays J Pathol; 2010 Dec;32(2):123-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A "tumour trifecta:" myelolipomata arising within an adrenocortical adenoma ipsilateral to a synchronous clear cell renal cell carcinoma.
  • We present an intriguing case of adrenal myelolipomata occurring within an adrenocortical adenoma in concert with an ipsilateral clear cell renal cell carcinoma.
  • Computed tomography indicated a 2.5 cm right renal mass as well as a 5 cm right adrenal mass.
  • Histology of the renal mass was consistent with conventional clear cell renal cell carcinoma, Fuhrman grade III.
  • There was no extra-renal extension or lymphovascular invasion.
  • The adrenal mass was a cortical adenoma with solid and nested patterns, with discrete zones consisting of erythroid, myeloid and megakaryocytic cells intermixed with mature adipocytes.
  • We also present a relevant review of the literature pertaining to adrenal lesions.
  • In particular, we emphasize the epidemiological, histological and immunohistochemical features that are helpful in determining the origin and malignant potential of adrenal lesions.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Myelolipoma / pathology. Neoplasms, Multiple Primary / pathology


50. Lichtenauer UD, Shapiro I, Geiger K, Quinkler M, Fassnacht M, Nitschke R, Rückauer KD, Beuschlein F: Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology; 2008 Mar;149(3):1314-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R.
  • Recent evidence suggests the existence of a stem cell-like subpopulation of cells in hematological and solid tumor entities, which determine the malignant phenotype of a given tumor through their proliferative potential and chemotherapy resistance.
  • A recently used technique for the isolation of this cell population is through exclusion of the vital dye Hoechst 33342, which defines the so-called side population (SP).
  • Herein we demonstrate the presence of SP cells in a variety of adrenal specimens, including primary cultures of human adrenocortical tumors and normal adrenal glands as well as established human and murine adrenocortical cancer cell lines by fluorescence-activated cell sorter analysis and confocal microscopy.
  • On a functional level, SP cells from the human adrenocortical tumor cell line NCI h295R revealed an expression pattern consistent with a less differentiated phenotype, including lower expression of steroidogenic enzymes such as steroid acute regulatory protein (StAR) and side-chain cleavage enzyme (P450scc) in comparison with non-SP cells.
  • Furthermore, re-sorting and tracing experiments revealed the capacity for both cell types to give rise to the original SP- and non-SP-containing cell population.
  • Similarly to the baseline growth kinetics, no survival benefit was evident in SP cells after treatment with cytotoxic agents commonly used in adrenocortical carcinomas.
  • Taken together, these findings provide evidence that Hoechst dye exclusion, in contrast to what has been reported for other tumor entities, is not a major tumor stem cell defining marker in adrenocortical NCI h295R tumor cells.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Neoplastic Stem Cells / cytology
  • [MeSH-minor] Adrenal Glands / cytology. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Cycle / physiology. Cell Differentiation / physiology. Cell Line, Tumor. Cell Proliferation. Cholesterol Side-Chain Cleavage Enzyme / metabolism. Coloring Agents. Drug Resistance, Neoplasm / physiology. Humans. Phenotype. Phosphoproteins / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063677.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Coloring Agents; 0 / Phosphoproteins; 0 / steroidogenic acute regulatory protein; EC 1.14.15.6 / Cholesterol Side-Chain Cleavage Enzyme
  •  go-up   go-down


51. Nunes ML, Rault A, Teynie J, Valli N, Guyot M, Gaye D, Belleannee G, Tabarin A: 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning. World J Surg; 2010 Jul;34(7):1506-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning.
  • BACKGROUND: 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) has been proposed for the evaluation of adrenal tumors.
  • However, only scarce data are available to evaluate its usefulness for the identification of primary adrenal carcinomas in patients with no previous history of cancer and equivocal tumors on computed tomography (CT) scan.
  • Twenty-three consecutive patients without previous history of cancer investigated for adrenal tumors without features of benign adrenocortical adenoma on CT scan but no obvious ACC underwent 18F-FDG PET.
  • The ratio of maxSUV adrenal tumor on maxSUV liver (adrenal/liver maxSUV ratio) during 18F-FDG PET was compared to Weiss pathological criteria.
  • RESULTS: Seventeen patients had an adrenal adenoma, 2 had small size adrenal carcinomas (<5 cm), 1 had an angiosarcoma, and 3 had noncortical benign lesions.
  • An adrenal/liver maxSUV ratio above 1.6 provided 100% sensitivity, 90% specificity, and 100% negative predictive value for the diagnosis of malignant tumor.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnostic imaging. Adrenal Gland Neoplasms / diagnostic imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adrenocortical Adenoma / diagnostic imaging. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2650-5 [16670169.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):871-7 [15572420.001]
  • [Cites] Radiology. 2005 Feb;234(2):479-85 [15671003.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2018-25 [18566816.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • [Cites] J Nucl Med. 2001 Jun;42(6):884-92 [11390552.001]
  • [Cites] Radiology. 2006 Mar;238(3):970-7 [16505394.001]
  • [Cites] Int J Clin Pract. 2007 May;61(5):802-9 [17343665.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1713-22 [19190108.001]
  • (PMID = 20396886.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


52. Lindström V, Brandt I, Lindhe O: Species differences in 3-methylsulphonyl-DDE bioactivation by adrenocortical tissue. Arch Toxicol; 2008 Mar;82(3):159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Species differences in 3-methylsulphonyl-DDE bioactivation by adrenocortical tissue.
  • The CYP11B1-activated adrenocortical toxicant 3-methylsulphonyl-DDE (3-MeSO2-DDE) is proposed as a lead compound for an improved chemotherapy for adrenocortical carcinoma.
  • We compared the binding of 3-MeSO2-[14C]DDE in the adrenal cortex of four rodent species; hamster, guinea pig, mouse and rat, using a precision-cut adrenal slice culture system ex vivo.
  • The results revealed major species differences since 3-MeSO2-[14C]DDE was extensively bound to the hamster adrenal tissue while the guinea pig adrenals were devoid of binding.
  • A high binding in mouse adrenal cortex was confirmed while binding in rat adrenal cortex was very weak.
  • Since CYP11B1 could be expressed in tissues other than the adrenal cortex, final toxicological characterization should be carried out in a species that can bioactivate this compound.
  • [MeSH-major] Adrenal Cortex / metabolism. Dichlorodiphenyl Dichloroethylene / analogs & derivatives

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18034334.001).
  • [ISSN] 0340-5761
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 4M7FS82U08 / Dichlorodiphenyl Dichloroethylene; 62938-14-1 / 1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene
  •  go-up   go-down


53. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S: Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol; 2009 Oct;161(4):513-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?
  • OBJECTIVE: To assess the performance of current clinical recommendations for the evaluation of an adrenal incidentaloma.
  • Eligible studies were those deemed most applicable to the clinical scenario of a patient referred to an endocrinologist for assessment of an incidentally detected adrenal mass.
  • RESULTS: The prevalence of functional and malignant lesions presenting as adrenal incidentaloma was similar to that quoted in most reviews, other than a lower incidence of adrenal carcinoma (1.9 vs 4.7%) and metastases (0.7 vs 2.3%).
  • The development of functionality or malignancy during follow-up was rare (<1% becoming functional and 0.2% becoming malignant).
  • The average recommended computed tomography (CT) scan follow-up exposes each patient to 23 mSv of ionising radiation, equating to a 1 in 430 to 2170 chance of causing fatal cancer.
  • This is similar to the chance of developing adrenal malignancy during 3-year follow-up of adrenal incidentaloma.
  • CONCLUSION: Current recommendations for evaluation of adrenal incidentaloma are likely to result in significant costs, both financial and emotional, due to high false-positive rates.
  • The dose of radiation involved in currently recommended CT scan follow-up confers a risk of fatal cancer that is similar to the risk of the adrenal becoming malignant.


54. Almeida MQ, Soares IC, Ribeiro TC, Fragoso MC, Marins LV, Wakamatsu A, Ressio RA, Nishi MY, Jorge AA, Lerario AM, Alves VA, Mendonca BB, Latronico AC: Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults. J Clin Endocrinol Metab; 2010 Mar;95(3):1458-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults.
  • BACKGROUND: Steroidogenic factor 1 (SF-1) is a key determinant of endocrine development and function of adrenal cortex.
  • SF-1 overexpression and gene amplification were previously demonstrated in a small group of pediatric adrenocortical tumors.
  • OBJECTIVE: Our objective was to determine the frequency of SF-1 protein expression and gene amplification in a large cohort of pediatric and adult adrenocortical tumors.
  • PATIENTS: SF-1 protein expression was assessed in a cohort of 103 adrenocortical tumors from 36 children and 67 adults, whereas gene amplification was studied in 38 adrenocortical tumors (17 from children).
  • RESULTS: A strong nuclear SF-1 expression was detected by tissue microarray in 56% (20 of 36) and 19% (13 of 67) of the pediatric and adult adrenocortical tumors, respectively (P = 0.0004).
  • Increased SF-1 copy number was identified in 47% (eight of 17) and 10% (two of 21) of the pediatric and adult adrenocortical tumors, respectively (P = 0.02).
  • All adrenocortical tumors with SF-1 gene amplification showed a strong SF-1 staining, whereas most of the tumors (61%) without SF-1 amplification displayed a weak or negative staining (P = 0.0008).
  • Interestingly, a strong SF-1 staining was identified in five (29%) pediatric adrenocortical tumors without SF-1 amplification.
  • The frequency of SF-1 overexpression and gene amplification was similar in adrenocortical adenomas and carcinomas.
  • CONCLUSION: We demonstrated a higher frequency of SF-1 overexpression and gene amplification in pediatric than in adult adrenocortical tumors, suggesting an important role of SF-1 in pediatric adrenocortical tumorigenesis.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Adenoma / genetics. Adrenocortical Carcinoma / genetics. Gene Amplification / genetics. Steroidogenic Factor 1 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20080844.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Steroidogenic Factor 1
  •  go-up   go-down


55. Else T, Giordano TJ, Hammer GD: Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. J Clin Endocrinol Metab; 2008 Apr;93(4):1442-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma.
  • CONTEXT: Adrenocortical cancer (ACC) is a rare disease with an often fatal outcome.
  • The clinical and pathological diagnosis of a malignant vs. benign adrenocortical tumor is sometimes challenging.
  • Telomere maintenance mechanisms (TMMs) are critical for the persistence of the malignant phenotype, but little is known about these mechanisms or their diagnostic value in adrenocortical lesions.
  • OBJECTIVE: Tissue samples of diagnostically known adrenocortical neoplasms were evaluated for parameters of known TMMs, telomerase activity (TA), and alternative telomere lengthening (ALT).
  • DESIGN: The study analyzed retrospectively collected frozen adrenocortical tissue samples from the University of Michigan Health System.
  • PATIENT SAMPLES: Samples included 24 ACCs, 11 adrenocortical adenomas (ACAs), and three normal adrenal tissues.
  • None of the normal adrenal tissues (none of three) or ACA (none of 11) samples had signs of an active TMM.
  • Determination of telomere maintenance mechanisms in diagnostically challenging adrenocortical tumors might be of additional diagnostic value in the pathological diagnosis of malignant vs. benign lesions.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Telomere

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18198226.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


56. Khan S, Imtiaz KE: Adrenocortical carcinoma: a diagnostic and treatment dilemma. Br J Hosp Med (Lond); 2009 Jan;70(1):46-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: a diagnostic and treatment dilemma.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Seeding

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357579.001).
  • [ISSN] 1750-8460
  • [Journal-full-title] British journal of hospital medicine (London, England : 2005)
  • [ISO-abbreviation] Br J Hosp Med (Lond)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Ishida M, Yoshida K, Miyamoto K, Iwai M, Miyahira Y, Kushima R, Okabe H: Cytological features of myxoid adrenocortical adenoma with a pseudoglandular component: a case report with differential diagnostic considerations. Diagn Cytopathol; 2008 Aug;36(8):576-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological features of myxoid adrenocortical adenoma with a pseudoglandular component: a case report with differential diagnostic considerations.
  • Myxoid adrenocortical tumors are extremely rare neoplasms with only nine adenomas and eleven carcinomas reported in the literature.
  • They occasionally have a pseudoglandular component resembling metastatic mucinous adenocarcinoma in the adrenal gland.
  • We report here the first cytopathological study of a myxoid adrenocortical adenoma with a pseudoglandular component, contributing especially to the differential diagnosis from metastatic mucinous adenocarcinoma.
  • Two major cytopathological features distinguishing myxoid adrenocortical adenoma from metastatic mucinous adenocarcinoma in the adrenal gland are:.
  • Careful observation of these cytological features and positive immunoreactivity to Melan A, alpha-inhibin and synaptophysin can lead to the correct diagnosis.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / diagnosis. Adrenocortical Adenoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618725.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Assié G, Guillaud-Bataille M, Ragazzon B, Bertagna X, Bertherat J, Clauser E: The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses. Trends Endocrinol Metab; 2010 May;21(5):325-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses.
  • Accumulating data on adrenal cortex and adrenocortical tumor transcriptomes have already identified striking transcriptome differences not only between adenoma and carcinoma but also between two sets of carcinoma, which have very different prognoses.
  • These transcriptome data observing adrenocortical tumor phenotype in great but complex detail, combined with genomic and proteomic information, will function for future research investigating the pathophysiology of their tumorigenesis and hormonal secretion.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenal Cortex Neoplasms / physiopathology. Gene Expression Profiling
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Adenoma / physiopathology. Adrenal Cortex / metabolism. Animals. Carcinoma / genetics. Carcinoma / pathology. Carcinoma / physiopathology. Humans. Hyperaldosteronism / physiopathology. Oligonucleotide Array Sequence Analysis. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20097573.001).
  • [ISSN] 1879-3061
  • [Journal-full-title] Trends in endocrinology and metabolism: TEM
  • [ISO-abbreviation] Trends Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


59. Cobb WS, Kercher KW, Sing RF, Heniford BT: Laparoscopic adrenalectomy for malignancy. Am J Surg; 2005 Apr;189(4):405-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The superiority of the minimally invasive approach to adrenal resections has been well documented for benign pathology.
  • With technical advances and increased experience, surgeons have successfully performed laparoscopic adrenalectomies for metastatic and primary malignancies of the adrenal gland.
  • The technique of laparoscopic adrenalectomy as it pertains to malignant lesions is presented.
  • A review of the literature demonstrates the safety and efficacy of laparoscopic adrenalectomy for metastatic colorectal, lung, and renal tumors.
  • For primary adrenal malignancies, radical resections can be effectively performed laparoscopically; however, continued long-term follow-up is needed to establish the minimally invasive technique as the preferred approach.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / pathology. Adrenocortical Carcinoma / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820450.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


60. Bagwan IN, Cook G, Mudan S, Wotherspoon A: Unusual presentation of metastatic adenocarcinoma. World J Surg Oncol; 2007;5:116
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of metastatic adenocarcinoma.
  • BACKGROUND: The most common tumours of the adrenal gland are adenoma, pheochromocytoma, adrenocortical carcinoma, and metastases.
  • Although the imaging features of these tumours are established, the imaging characteristics of uncommon adrenal masses are less well known.
  • In patients with extradrenal tumour, incidental discovery of an adrenal mass necessitates excluding the possibility of metastatic malignancy.
  • CASE PRESENTATION: A 52 year-old female was diagnosed with oesophageal adenocarcinoma and treated with oesophagectomy and adjuvant chemotherapy.
  • Sixteen months later on staging CT scan a 2 x 2 cm adrenal mass was detected, which increased in size over a period of time to 3 x 3 cm in size.
  • Adrenalectomy was performed and histological examination revealed metastatic adenocarcinoma within an adrenal adenoma.
  • CONCLUSION: The present case highlights the unusual behaviour of an oesophageal adenocarcinoma causing metastasis to an adrenocortical adenoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adrenal Gland Neoplasms / secondary. Esophageal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 2005 Dec;52(6):785-8 [16410674.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1624-33 [16518827.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1795-9 [11752075.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] AJR Am J Roentgenol. 1996 Oct;167(4):891-2 [8819376.001]
  • [Cites] Surgery. 2004 Dec;136(6):1289-96 [15657589.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4924-9 [15914530.001]
  • (PMID = 17949483.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2100056
  •  go-up   go-down


61. McNicol AM: A diagnostic approach to adrenal cortical lesions. Endocr Pathol; 2008;19(4):241-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A diagnostic approach to adrenal cortical lesions.
  • The adrenal gland is not a common specimen in surgical pathology practice as, until recently, adrenal tumors were recognized in life only if associated with hypersecretion of hormones or evidence of malignancy.
  • However, adrenal nodules are not uncommon at autopsy, and the number of these found in life is now increasing as they are identified when the abdomen is scanned for the investigation of other diseases using computed tomography or magnetic resonance imaging.
  • It is therefore becoming increasingly important for the surgical pathologist to be aware of the range of pathology in the gland and to understand how to approach the specimens.
  • This short review will deal with lesions of the adrenal cortex.
  • [MeSH-major] Adrenal Cortex / pathology. Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Adrenal Medulla / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Renal Cell / diagnosis. Diagnosis, Differential. Humans. Kidney Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Pheochromocytoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Med Scand. 1968 Sep;184(3):211-4 [5703975.001]
  • [Cites] Tohoku J Exp Med. 1996 Jun;179(2):123-9 [8875768.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4970-3 [11600572.001]
  • [Cites] Lab Invest. 1995 Apr;72(4):424-31 [7723281.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):685-9 [1311000.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Histopathology. 2007 Aug;51(2):239-45 [17593212.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Mar;78(3):790-4 [8126158.001]
  • [Cites] Endocr Pathol. 1998 Autumn;9(3):235-239 [12114714.001]
  • [Cites] Intern Med. 1997 Jun;36(6):398-402 [9213185.001]
  • [Cites] Endocrinol Metab Clin North Am. 1991 Jun;20(2):247-55 [1879397.001]
  • [Cites] Br J Cancer. 1999 Oct;81(4):684-9 [10574256.001]
  • [Cites] Endocr Res. 1998 Aug-Nov;24(3-4):963-7 [9888607.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):408-10 [8509216.001]
  • [Cites] Eur J Endocrinol. 2001 Aug;145(2):207-12 [11454518.001]
  • [Cites] Horm Res. 1997;47(4-6):269-72 [9167963.001]
  • [Cites] Eur J Endocrinol. 1997 Mar;136(3):296-303 [9100555.001]
  • [Cites] CA Cancer J Clin. 1987 Nov-Dec;37(6):348-65 [3119168.001]
  • [Cites] Braz J Med Biol Res. 2000 Oct;33(10):1249-52 [11004727.001]
  • [Cites] Endocr Pathol. 1997 Spring;8(1):29-36 [12114669.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2001 Dec;28(12):1083-6 [11903321.001]
  • [Cites] Pathol Int. 1995 Mar;45(3):240-6 [7787995.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):860-4 [7828138.001]
  • [Cites] Mol Genet Metab. 2001 Sep-Oct;74(1-2):206-16 [11592817.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):530-6 [9195568.001]
  • [Cites] Neurochem Res. 2003 Feb;28(2):327-32 [12608705.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Dec;11(4):330-3 [14663359.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1088:319-34 [17192577.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Crit Rev Clin Lab Sci. 1999 Aug;36(4):329-63 [10486704.001]
  • [Cites] Am J Med Genet. 1998 Oct 2;79(4):253-9 [9781904.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2559-65 [9253334.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):196-203 [16249277.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):973-8 [12218215.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6762-7 [11559548.001]
  • [Cites] J Endocrinol Invest. 2006 Apr;29(4):298-302 [16699294.001]
  • [Cites] Am J Clin Pathol. 1999 Oct;112(4):451-5 [10510668.001]
  • [Cites] N J Med. 1995 Jan;92 (1):33-6 [7854572.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Ann R Coll Surg Engl. 1958 Sep;23(3):155-86 [13571886.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1060-5 [9569040.001]
  • [Cites] J Urol. 1978 Dec;120(6):660-5 [731800.001]
  • [Cites] Lancet. 2005 Jun 18-24;365(9477):2125-36 [15964450.001]
  • [Cites] J Pathol. 1969 Sep;99(1):1-18 [5359219.001]
  • [Cites] J Urol. 1979 Jul;122(1):87-91 [458997.001]
  • [Cites] Endocr Rev. 1995 Aug;16(4):460-84 [8521790.001]
  • [Cites] Pituitary. 2004;7(4):225-35 [16010457.001]
  • [Cites] JAMA. 1973 Mar 5;223(10):1109-12 [4739370.001]
  • [Cites] J Endocrinol. 1999 May;161(2):341-7 [10320833.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):549-56 [1755111.001]
  • [Cites] Mol Genet Metab. 2003 Feb;78(2):83-92 [12666684.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3134-43 [9745416.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):603-14 [9591731.001]
  • [Cites] Am J Clin Pathol. 1991 Sep;96(3):334-40 [1652202.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):455-60; discussion 460-1 [7725728.001]
  • [Cites] Metabolism. 2002 Mar;51(3):350-5 [11887172.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4219-23 [8797595.001]
  • [Cites] J Pathol. 1997 Feb;181(2):146-52 [9120717.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Dec;43(6):753-8 [8736280.001]
  • [Cites] Am J Med Sci. 1997 Nov;314(5):338-41 [9365337.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):585-98 [16172193.001]
  • [Cites] Endocr Res. 1998 Aug-Nov;24(3-4):851-6 [9888586.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):338-52 [8001005.001]
  • [Cites] Endocr Pathol. 2006 Winter;17 (4):345-54 [17525483.001]
  • [Cites] J Clin Pathol. 1998 Feb;51(2):114-6 [9602683.001]
  • [Cites] Horm Metab Res. 1998 Oct;30(10):619-23 [9851669.001]
  • [Cites] Am J Med. 1966 Oct;41(4):572-80 [5923598.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3467-74 [12107267.001]
  • [Cites] J Pathol Bacteriol. 1959 Oct;78:533-41 [13807902.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):838-43 [16819325.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):747-9 [2259385.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):216-9 [9920087.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Endocr Res. 1998 Aug-Nov;24(3-4):865-7 [9888589.001]
  • [Cites] Ann Intern Med. 1999 May 4;130(9):759-71 [10357696.001]
  • [Cites] Intern Med. 1992 Jun;31(6):803-6 [1327310.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Sep;77(3):852-8 [8370710.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Endocr Pathol. 2001 Winter;12(4):397-406 [11914473.001]
  • [Cites] J Urol. 1993 Jun;149(6):1389-94 [8501773.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 19089656.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 88
  •  go-up   go-down


62. Giordano TJ: Adrenocortical tumors: an integrated clinical, pathologic, and molecular approach at the University of Michigan. Arch Pathol Lab Med; 2010 Oct;134(10):1440-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical tumors: an integrated clinical, pathologic, and molecular approach at the University of Michigan.
  • Recently, an integrated clinical and research program focused on primary cancer of the adrenal gland has been developed.
  • OBJECTIVE: To discuss the foundation of the University of Michigan Adrenal Cancer Program that consists of 3 components:.
  • DATA SOURCES: Recent programmatic activity includes genome-wide transcriptomic evaluation of human adrenocortical tumors for diagnostic and prognostic evaluation; interrogation of the Wnt signaling pathway in adrenocortical carcinoma, using mouse models and transcriptome profiling; and clinical trials with targeted therapy focused on inhibition of insulin-like growth factor signaling pathway.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenal Cortex Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20923297.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


63. Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, Miceli R, Muleti A, Amendola D, Piergrossi P, Brunetti E, Toscano V, Stigliano A: Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr Relat Cancer; 2008 Jun;15(2):623-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
  • This drug and radiotherapy are used also in adrenal cancer treatment even if their biological action in this neoplasia remains unknown.
  • We investigated the effects of o,p'-DDD and ionizing radiations (IR) on cell growth inhibition and cell cycle perturbation in H295R and SW13 adrenocortical cancer cells.
  • Both cell lines were irradiated at a 6 Gy dose and were treated with o,p'-DDD 10(-5) M separately and with IR/o,p'-DDD in combination.
  • This combination treatment induced an irreversible inhibition of cell growth in both adrenocortical cancer cells.
  • Cell cycle analysis showed that IR alone and IR/o,p'-DDD in combination induced the cell accumulation in the G2 phase.
  • In order to study the molecular mechanism involved in the G2 irreversible arrest, we have considered the H295R cell line showing the highest inhibition of cell proliferation associated with a noteworthy G2 arrest.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Antineoplastic Agents, Hormonal / pharmacology. Mitotane / pharmacology. Radiotherapy
  • [MeSH-minor] CDC2 Protein Kinase / metabolism. Cell Division / drug effects. Cell Division / radiation effects. Cell Line, Tumor. Cyclin B / metabolism. Cyclin B1. G2 Phase / drug effects. G2 Phase / radiation effects. Humans. RNA, Messenger / metabolism. Steroids / pharmacology. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. MITOTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509009.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / CCNB1 protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / RNA, Messenger; 0 / Steroids; 0 / Tumor Suppressor Protein p53; 78E4J5IB5J / Mitotane; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


64. Beuschlein F: Adrenal incidentalomas: presentation and clinical work-up. Horm Res; 2007;68 Suppl 5:191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal incidentalomas: presentation and clinical work-up.
  • BACKGROUND: Through the widespread use of imaging techniques with great sensitivity, adrenal tumours are often diagnosed as an incidental finding.
  • The majority of these adrenal lesions are benign and without evidence of endocrine activity or malignancy.
  • However, in addition to the classic forms of overt adrenal hypersecretion, it has become evident in recent years that even modest adrenal hormonal autonomy, as exhibited in clinically silent phaeochromocytoma, normokalaemic primary aldosteronism and subclinical Cushing syndrome, is associated with significant morbidity.
  • CONCLUSIONS: Detection and differential diagnosis of subtle changes in adrenal hormone secretion can pose a diagnostic challenge to the clinician, and accurate diagnosis is dependent on use of tests with reliable sensitivity and specificity.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / diagnosis. Incidental Findings
  • [MeSH-minor] Adrenocortical Carcinoma / complications. Adrenocortical Carcinoma / diagnosis. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Pheochromocytoma / complications. Pheochromocytoma / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 18174744.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 42
  •  go-up   go-down


65. Zhang L, Liu M, Merling R, Giam CZ: Versatile reporter systems show that transactivation by human T-cell leukemia virus type 1 Tax occurs independently of chromatin remodeling factor BRG1. J Virol; 2006 Aug;80(15):7459-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Versatile reporter systems show that transactivation by human T-cell leukemia virus type 1 Tax occurs independently of chromatin remodeling factor BRG1.
  • Potent activation of human T-cell leukemia virus type 1 (HTLV-1) gene expression is mediated by the virus-encoded transactivator protein Tax and three imperfect 21-bp repeats in the viral long terminal repeats.
  • Using an easily transduced and chromosomally integrated reporter system derived from a self-inactivating lentivirus vector, we showed in a BRG1- and BRM1-deficient adrenal carcinoma cell line, SW-13, that Tax- and 21-bp repeat-mediated transactivation does not require BRG1 or BRM1 and is not enhanced by BRG1.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Oct 26;19(45):5198-203 [11064457.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13075-82 [16547351.001]
  • [Cites] Mol Cell. 2001 Feb;7(2):401-9 [11239468.001]
  • [Cites] Curr Biol. 2001 Mar 6;11(5):R185-97 [11267889.001]
  • [Cites] Oncogene. 2001 May 28;20(24):3047-54 [11420720.001]
  • [Cites] Science. 2001 Aug 24;293(5534):1495-9 [11520989.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23):6805-15 [11726516.001]
  • [Cites] J Virol. 2002 Dec;76(24):12564-73 [12438582.001]
  • [Cites] J Biol Chem. 2003 Jan 17;278(3):1487-93 [12419799.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):7422-30 [12493776.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2055-67 [12612078.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):495-508 [14530271.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30099-105 [15140882.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] J Natl Cancer Inst. 1973 Aug;51(2):691-7 [4765382.001]
  • [Cites] J Biol Chem. 1989 Sep 15;264(26):15236-41 [2768259.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11445-9 [1763059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):610-4 [8421695.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7303-7 [8346248.001]
  • [Cites] Science. 1993 Oct 15;262(5132):395-9 [8211160.001]
  • [Cites] EMBO J. 1993 Nov;12(11):4279-90 [8223438.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):456-62 [8264613.001]
  • [Cites] J Mol Biol. 1994 Feb 25;236(3):685-90 [8114086.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5642-6 [8202541.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5820-31 [7520526.001]
  • [Cites] Nature. 1995 Aug 17;376(6541):602-5 [7637811.001]
  • [Cites] Nature. 1995 Aug 17;376(6541):606-8 [7637812.001]
  • [Cites] J Virol. 1995 Oct;69(10):6209-18 [7666522.001]
  • [Cites] Nature. 1996 Apr 18;380(6575):642-6 [8602268.001]
  • [Cites] Mol Cell Biol. 1996 Jun;16(6):3156-68 [8649426.001]
  • [Cites] J Mol Biol. 1996 Nov 22;264(1):20-31 [8950264.001]
  • [Cites] Mol Cell Biol. 1998 Feb;18(2):721-31 [9447968.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2392-405 [9528808.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13768-75 [9593719.001]
  • [Cites] J Mol Biol. 1999 Oct 22;293(2):187-98 [10529347.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34226-32 [10567395.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8136-45 [10567539.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6948-58 [10602469.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):15891-4 [9632633.001]
  • [Cites] Cell. 1998 Jun 26;93(7):1231-40 [9657155.001]
  • [Cites] J Biol Chem. 1998 Jul 24;273(30):19251-9 [9668114.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11852-7 [10766811.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1899-907 [10921904.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):541-4 [10952318.001]
  • [Cites] J Virol. 2000 Sep;74(18):8277-85 [10954525.001]
  • [Cites] Cell. 2000 Sep 1;102(5):587-98 [11007477.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2441-51 [11018012.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34060-7 [10906125.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4629-38 [9671473.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):498-502 [9697775.001]
  • [Cites] J Biol Chem. 1998 Aug 14;273(33):21132-6 [9694868.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5052-61 [9710589.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27339-46 [9765261.001]
  • [Cites] Bioessays. 1998 Sep;20(9):771-80 [9819566.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):855-63 [9858608.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1341-9 [10022816.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17402-5 [10364167.001]
  • [Cites] J Virol Methods. 2005 Jan;123(1):17-24 [15582694.001]
  • [Cites] Biochem Cell Biol. 2005 Aug;83(4):405-17 [16094444.001]
  • [Cites] J Cell Biochem. 2006 Mar 1;97(4):684-9 [16365876.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1695-700 [11080812.001]
  • (PMID = 16840326.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / F32 GM075688; United States / NCI NIH HHS / CA / R01 CA048709; United States / NCI NIH HHS / CA / R01 CA 48709; United States / NCI NIH HHS / CA / R01 CA/GM 75688
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Activating Transcription Factors; 0 / CREB1 protein, human; 0 / Chromatin; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Gene Products, tax; 0 / Histones; 0 / NF-kappa B; 0 / Nuclear Proteins; 0 / SMARCA2 protein, human; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; EC 3.6.1.- / SMARCA4 protein, human; EC 3.6.4.- / DNA Helicases
  • [Other-IDs] NLM/ PMC1563696
  •  go-up   go-down


66. Shen WT, Sturgeon C, Duh QY: From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol; 2005 Mar 1;89(3):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors.
  • In this article we review the management of benign and malignant adrenal tumors, with an emphasis on oncologic concerns.
  • Concise, logical guidelines for the diagnosis and operative treatment of incidentalomas, aldosteronomas, adrenal Cushing syndrome, virilizing and feminizing adrenal tumors, isolated adrenal metastases, and adrenocortical carcinoma are provided.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Laparoscopy
  • [MeSH-minor] Adrenal Gland Neoplasms / radiography. Adrenal Gland Neoplasms / secondary. Adrenocorticotropic Hormone / blood. Aldosterone / blood. Cushing Syndrome / diagnosis. Humans. Incidental Findings. Magnetic Resonance Imaging. Radiography, Abdominal. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15719374.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone; 9002-60-2 / Adrenocorticotropic Hormone
  • [Number-of-references] 32
  •  go-up   go-down


67. Sawhney S, Burney I, Jain R: Pulmonary Infarction: A rare case of adrenal carcinoma. Sultan Qaboos Univ Med J; 2007 Apr;7(1):55-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary Infarction: A rare case of adrenal carcinoma.
  • A case report of unsuspected adrenal carcinoma with pulmonary artery obstruction in a young girl who was admitted with recurrent episodes of hypotension is presented.
  • Computed tomography (CT) scans demonstrated a large right adrenal mass extending into the inferior vena cava (IVC), right atrium, right ventricle and right pulmonary artery.
  • There are many case reports in literature documenting IVC and right atrial thrombus in patients with adrenal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Urol Nephrol. 2002 Feb;36(1):71-3 [12002362.001]
  • [Cites] Acta Radiol. 2003 Mar;44(2):160-1 [12694101.001]
  • [Cites] World J Surg. 1986 Jun;10(3):496-500 [3727611.001]
  • [Cites] J Pediatr Surg. 1974 Feb;9(1):59-67 [4359550.001]
  • [Cites] Emerg Radiol. 2003 Apr;10(1):43-5 [15290530.001]
  • [Cites] J Urol. 2003 Jun;169(6):2296-7 [12771776.001]
  • (PMID = 21654947.001).
  • [ISSN] 2075-051X
  • [Journal-full-title] Sultan Qaboos University medical journal
  • [ISO-abbreviation] Sultan Qaboos Univ Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3086421
  • [Keywords] NOTNLM ; Adrenal carcinoma / Case report / Computed Tomography / Oman / Pulmonary infarction
  •  go-up   go-down


68. Wang Y, Nicholls PK, Stanton PG, Harrison CA, Sarraj M, Gilchrist RB, Findlay JK, Farnworth PG: Extra-ovarian expression and activity of growth differentiation factor 9. J Endocrinol; 2009 Sep;202(3):419-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present studies confirm GDF9 expression in the mouse testis, pituitary gland and adrenocortical cancer (AC) cells, and establish its expression in L beta T2 gonadotrophs, and in mouse adrenal glands, particularly foetal and neonatal cortical cells.
  • We therefore compared GDF9 activation of these potential extra-ovarian target cell types with its activation of granulosa cells.
  • Recombinant mouse GDF9 stimulated expression of activin/transforming growth factor-beta-responsive reporters, pGRAS-luc or pAR3-lux, in TM4 and AC cells (IC50=145 ng/ml in the latter case), and two granulosa cell lines, KGN and COV434.
  • Our findings show that GDF9 regulates the expression of R-SMAD2/3-responsive reporter genes through ALK4, 5 or 7 in extra-ovarian (adrenocortical and Sertoli) cells with similar potency and signalling pathway to its actions on granulosa cells, but suggest that expression of BMPRII, ALK5 (TGFBR1) and R-SMADs 2 and 3 may not be sufficient for a cell to respond to GDF9.
  • [MeSH-major] Adrenal Glands / physiology. Growth Differentiation Factor 9 / genetics. Leydig Cells / physiology. Pituitary Gland / physiology. Sertoli Cells / physiology

  • Hazardous Substances Data Bank. MENOTROPINS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19505950.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide; 0 / Benzamides; 0 / Dioxoles; 0 / GDF9 protein, human; 0 / Gdf9 protein, mouse; 0 / Gdf9 protein, rat; 0 / Growth Differentiation Factor 9; 9002-68-0 / Follicle Stimulating Hormone; EC 1.13.12.- / Luciferases
  •  go-up   go-down


69. Boesch C, Vermathen P, Kreis R: Insufficient spectral quality to draw conclusions. Radiology; 2009 Mar;250(3):955-6; author reply 955-6; discussion 956
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / diagnosis. Adrenal Gland Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis. Pheochromocytoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Prospective Studies. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Radiology. 2007 Dec;245(3):788-97 [18024453.001]
  • (PMID = 19244058.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


70. McLaughlin SA, Schmitt TM, Huguet KL, Menke DM, Nguyen JH: Myofibrosarcoma of the adrenal gland. Am Surg; 2005 Mar;71(3):191-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myofibrosarcoma of the adrenal gland.
  • Adrenal masses have varying presentations.
  • Most commonly, adrenal masses are discovered incidentally on CT or MRI during an evaluation for an unrelated complaint.
  • Although the majority of these are nonfunctional cortical adenomas, hormonally active tumors and adrenocortical carcinoma must also be considered in the differential diagnosis.
  • Rarely, retroperitoneal tumors may mimic an adrenal mass.
  • We report a case of a 49-year-old man with anemia and weight loss who was found to have a large retroperitoneal mass arising from the adrenal gland.
  • Surgical treatment involved en bloc resection of the right kidney, adrenal gland, segments 7 and 8 of the liver, and a portion of the right hemidiaphragm.
  • We believe that this is the first case report of a myofibrosarcoma of the adrenal gland.
  • Myofibrosarcomas are rare malignant tumors composed of myofibroblasts that arise from the deep soft tissues.
  • We will briefly discuss the workup of an adrenal mass and focus on the diagnosis of myofibrosarcoma.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Myosarcoma / pathology. Myosarcoma / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869129.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 6
  •  go-up   go-down


71. Ota K, Satoh H, Lin SY, Fujita J, Ohara G, Kurishima K, Hizawa N: Endobronchial metastasis from adrenocortical carcinoma. Intern Med; 2009;48(13):1161-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial metastasis from adrenocortical carcinoma.
  • We present herein a case of endobronchial metastasis from adrenocortical carcinoma.
  • In the English language literature, this is the first case with such rare metastasis from adrenocortical carcinoma diagnosed antemortem.
  • Although very rare, physicians should keep in mind the possibility of endobronchial metastasis in patients with a history of extrapulmonary malignancy including adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms. Bronchial Neoplasms / secondary

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571451.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


72. Korzeniewska M, Kołomecki K, Stepień H, Naze M, Stepień T, Kuzdak K: [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors]. Endokrynol Pol; 2005 Jan-Feb;56(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors].
  • [Transliterated title] Ocena stezeń wybranych czynników pro i antyangiogennych we krwi u chorych z nieczynnymi hormonalnie guzami nadnerczy.
  • THE AIM OF THE STUDY: Evaluation the value of serum VEGF and soluble forms of VEGF receptors concentration as a marker of malignancy in patients with hormonal inactive adrenal tumors.
  • MATERIAL AND METHODS: Twenty seven patients (18 female, 9 male; mean age 48+/-4.3 years) with adrenocortical carcinoma (N=8), adrenal metastases (N=4) and adrenocortical adenoma (N=15) were included in this study.
  • Patients with adrenocortical carcinoma had the levels of VEGF (1263.8 pg/ml) significantly higher and of sVEGFR-2 (5893.7 pg/ml) significantly lower in comparison to control group (p<0.05).
  • On the other hand the mean VEGF (334.2 pg/ml) concentration in patients with benign adrenocortical adenoma wasn't significant different than in control group (p>0.05) but mean sVEGFR-1 (21.7 pg/ml) and sVEGFR-2 (7106.4 pg/ml) concentrations were significantly lower than in the control (p<0.05).
  • CONCLUSION: These data suggest that determination of VEGF and sVEGFR concentration in the serum of patients with hormonal inactive adrenal tumors may be applied as an additional marker of malignancy.
  • [MeSH-major] Adrenal Cortex Neoplasms / blood. Adrenal Cortex Neoplasms / pathology. Biomarkers, Tumor / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adrenocortical Adenoma / blood. Adrenocortical Adenoma / pathology. Adrenocortical Carcinoma / blood. Adrenocortical Carcinoma / pathology. Adrenocortical Carcinoma / secondary. Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Vascular Endothelial Growth Factor Receptor-1 / blood. Vascular Endothelial Growth Factor Receptor-2 / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16335673.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


73. Li R, Johnson AB, Salomons G, Goldman JE, Naidu S, Quinlan R, Cree B, Ruyle SZ, Banwell B, D'Hooghe M, Siebert JR, Rolf CM, Cox H, Reddy A, Gutiérrez-Solana LG, Collins A, Weller RO, Messing A, van der Knaap MS, Brenner M: Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol; 2005 Mar;57(3):310-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease.
  • Alexander disease is a progressive, usually fatal neurological disorder defined by the widespread and abundant presence in astrocytes of protein aggregates called Rosenthal fibers.
  • The disease most often occurs in infants younger than 2 years and has been labeled a leukodystrophy because of an accompanying severe myelin deficit in the frontal lobes.
  • Recently, we and others have found pathogenic, de novo missense mutations in the glial fibrillary acidic protein gene in most infantile patients examined and in a few later onset patients.
  • To obtain further information about the role of glial fibrillary acidic protein mutations in Alexander disease, we analyzed 41 new patients and another 3 previously described clinically, including 18 later onset patients.
  • Our results show that dominant missense glial fibrillary acidic protein mutations account for nearly all forms of this disorder.
  • They also significantly expand the catalog of responsible mutations, verify the value of magnetic resonance imaging diagnosis, indicate an unexpected male predominance for the juvenile form, and provide insights into phenotype-genotype relations.
  • [MeSH-major] Alexander Disease / genetics. Glial Fibrillary Acidic Protein / genetics. Mutation, Missense
  • [MeSH-minor] Adolescent. Adrenocortical Carcinoma. Adult. Age Factors. Age of Onset. Cell Line, Tumor. Child. Child, Preschool. DNA Mutational Analysis / methods. Female. Humans. Infant. Magnetic Resonance Imaging / methods. Male. Middle Aged. Models, Molecular. Mutagenesis / physiology. Transfection / methods

  • Genetic Alliance. consumer health - Alexander Disease.
  • Genetics Home Reference. consumer health - Alexander disease.
  • Genetics Home Reference. consumer health - GFAP gene.
  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Neurol. 2005 Mar;57(3):307-8 [15732119.001]
  • (PMID = 15732097.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / N01 HD 43368; United States / NICHD NIH HHS / HD / N01 HD 83284; United States / NINDS NIH HHS / NS / P01 NS 42803; United States / NICHD NIH HHS / HD / P30 HD 38985; United States / NINDS NIH HHS / NS / R01 NS 39055
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


74. Strosberg JR, Hammer GD, Doherty GM: Management of adrenocortical carcinoma. J Natl Compr Canc Netw; 2009 Jul;7(7):752-8; quiz 759
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adrenocortical carcinoma.
  • Adrenocortical carcinomas (ACCs) are rare tumors that arise from the cortex of the adrenal gland with an incidence 1 to 2 per million.
  • This article describes the basic diagnostic and prognostic issues in adrenal cancer management, and presents detailed rationales for therapeutic management.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / therapy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19635227.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Catecholamines; 5001-33-2 / Metanephrine; 78E4J5IB5J / Mitotane; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


75. Sangoi AR, McKenney JK: A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am J Surg Pathol; 2010 Mar;34(3):423-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma.
  • We have encountered an increasing number of image-guided adrenal mass biopsies in which the differential diagnosis is adrenal cortical lesion versus pheochromocytoma.
  • In this study, a detailed immunoprofile of 63 adrenal cortical lesions (3 adrenal rests, 6 adrenal cortical hyperplasias, 43 adrenal cortical adenomas, 4 adrenal cortical neoplasms of uncertain malignant potential, and 7 adrenal cortical carcinomas) was compared with 35 pheochromocytomas using traditional (calretinin, chromogranin, inhibin, melanA, and synaptophysin) and novel [steroidogenic factor-1 (SF-1), microtubule-associated protein 2, and mammalian achaete-scute homolog-1] antibodies, using tissue microarray technology to simulate small image-guided biopsies.
  • Staining results based on a > or = 1+ and (> or = 2+) intensity threshold were as follows: calretinin-95% (89%) in adrenal cortical lesions and 14% (0%) in pheochromocytomas; chromogranin-0% in adrenal cortical lesions and 100% in pheochromocytomas; inhibin-97% (86%) in adrenal cortical lesions and 6% (0%) in pheochromocytomas; microtubule-associated protein 2-29% (16%) in adrenal cortical lesions and 100% (89%) in pheochromocytomas; mammalian achaete-scute homolog-1-0% in both adrenal cortical lesions and pheochromocytomas; melanA-94% (86%) in adrenal cortical lesions and 6% (0%) in pheochromocytomas; SF-1-87% (86%) in adrenal cortical lesions and 0% in pheochromocytomas; synaptophysin-67% (59%) in adrenal cortical lesions and 100% in pheochromocytomas.
  • Using an antibody panel consisting of chromogranin plus the nuclear antibody SF-1 and either calretinin or inhibin, while requiring a high-staining intensity threshold, helps to eliminate interpretative issues of artifactual or background reactivity, improves diagnostic sensitivity/specificity, and makes for an effective immunohistochemical approach in distinguishing adrenal cortical lesions from pheochromocytomas.
  • [MeSH-major] Adenoma / chemistry. Adrenal Cortex Neoplasms / chemistry. Adrenal Gland Neoplasms / chemistry. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Immunohistochemistry. Pheochromocytoma / chemistry. Tissue Array Analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Artifacts. Biopsy. Calbindin 2. Child. Child, Preschool. Chromogranins / analysis. Diagnosis, Differential. Female. Humans. Infant. Inhibins / analysis. Male. Middle Aged. Predictive Value of Tests. S100 Calcium Binding Protein G / analysis. Sensitivity and Specificity. Steroidogenic Factor 1 / analysis. Young Adult

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154585.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Chromogranins; 0 / NR5A1 protein, human; 0 / S100 Calcium Binding Protein G; 0 / Steroidogenic Factor 1; 57285-09-3 / Inhibins
  •  go-up   go-down


76. McDougal WS: Ruptured adrenocortical carcinoma as a cause of paediatric acute abdomen. J Urol; 2005 Mar;173(3):984
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ruptured adrenocortical carcinoma as a cause of paediatric acute abdomen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Surg Int. 2002 Dec;18(8):730-2 [12598975.001]
  • (PMID = 15711359.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Kuruba R, Gallagher SF: Current management of adrenal tumors. Curr Opin Oncol; 2008 Jan;20(1):34-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of adrenal tumors.
  • PURPOSE OF REVIEW: Adrenal tumors evoke considerable interest and diagnostic challenges.
  • This rare group of tumors includes functional tumors with a gamut of clinical presentations, as well as adrenocortical carcinoma, with its advanced disease at presentation and dismal prognosis posing additional challenge.
  • RECENT FINDINGS: Significant advances have been made in diagnostic imaging modalities for identifying malignancy risk in adrenal incidentalomas.
  • Considerable progress has occurred in understanding adrenocortical carcinoma pathogenesis from the study of genetics at the germline level in familial carcinomas, as well as at the somatic level by analyzing molecular alterations in sporadic tumors; this research supplies opportunities to develop novel therapeutic agents against a tumor with poor prognosis.
  • SUMMARY: Laparoscopic adrenalectomy has emerged as standard of care in the treatment of functional benign adenomas and nonfunctional tumors larger than 4 cm when adrenocortical carcinoma is not suspected.
  • Open adrenalectomy with en-bloc excision has been the mainstay for primary and recurrent adrenocortical carcinoma due to the lack of effective adjuvant therapy.
  • International consensus conferences have attempted to standardize diagnostic and treatment approaches in the management of adrenal tumors; further research is necessary.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / drug therapy
  • [MeSH-minor] Adrenal Glands / pathology. Adrenal Glands / radiography. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / genetics. Chemotherapy, Adjuvant. Humans. Pheochromocytoma / diagnosis. Pheochromocytoma / drug therapy. Prognosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043254.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


78. Martarelli D, Pompei P, Mazzoni G: Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197. Chemotherapy; 2009;55(6):425-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197.
  • BACKGROUND: In this study, we investigated the effect of CRM197 treatment in human adrenocortical carcinoma (AC) implanted in nude mice.
  • The effects on cell invasion and migration were investigated with a matrigel invasion assay.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents / pharmacology. Bacterial Proteins / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Cell Movement / drug effects. Drug Screening Assays, Antitumor. Gene Expression Regulation, Neoplastic. Heparin-binding EGF-like Growth Factor. Humans. Intercellular Signaling Peptides and Proteins / genetics. Male. Mice. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Diphtheria.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996587.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bacterial Proteins; 0 / HBEGF protein, human; 0 / Hbegf protein, mouse; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 92092-36-9 / CRM197 (non-toxic variant of diphtheria toxin)
  •  go-up   go-down


79. Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, Connolly LP, Kunter G, Rodriguez-Galindo C, Wallis JW, Hurwitz CA, Schteingart DE: Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab; 2006 Jul;91(7):2665-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.
  • CONTEXT: Adrenocortical carcinomas are uncommon, and their evaluation by [(18)F]fluorodeoxyglucose positron emission tomography (FDG PET) has not been well evaluated.
  • OBJECTIVE: The purpose of this study was to examine the potential utility of FDG PET in the detection of recurrent or metastatic adrenocortical carcinoma.
  • DESIGN: In patients with known adrenocortical carcinoma who underwent FDG-PET imaging for suspected recurrence or metastasis, FDG activity was compared with other imaging findings, clinical features, and the presence or absence of disease as confirmed by resection, biopsy, or clinical follow-up.
  • One patient with no abnormal FDG activity had a morphological abnormality subsequently proven to be a postoperative scar.
  • CONCLUSIONS: Most adrenocortical carcinomas accumulate and retain FDG and thus can be visualized by PET.
  • [MeSH-major] Adrenal Cortex Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621901.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R25 CA23944; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / CA 54216; United States / NCRR NIH HHS / RR / M01-RR00042
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


80. Chamuleau SA, Corssmit EP, Pereira AM, van de Berg BT, Siegert CE: A young woman with a severe bilateral pneumonia as the presenting sign of an adrenal carcinoma. Neth J Med; 2008 Mar;66(3):121-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A young woman with a severe bilateral pneumonia as the presenting sign of an adrenal carcinoma.
  • Additional diagnostic procedures accidentally revealed a large adrenal carcinoma and hypercortisolism.
  • The adrenal carcinoma was surgically removed, and she received mitotane treatment.
  • This severe and life-threatening infection was the first sign of an immunosuppressive state as part of Cushing's syndrome due to the adrenal carcinoma.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / diagnosis. Carcinoma / complications. Carcinoma / diagnosis. Cushing Syndrome / complications. Immunocompromised Host. Pneumonia / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349468.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


81. Kaneko T, Kojima Y, Umemoto Y, Sasaki S, Hayashi Y, Kohri K: Usefulness of transcription factors Ad4BP/SF-1 and DAX-1 as immunohistologic markers for diagnosis of advanced adrenocortical carcinoma. Horm Res; 2008;70(5):294-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of transcription factors Ad4BP/SF-1 and DAX-1 as immunohistologic markers for diagnosis of advanced adrenocortical carcinoma.
  • BACKGROUND: We examined the expressions of Ad4BP/SF-1 and DAX-1 in primary and metastatic lesions of advanced adrenocortical carcinoma with normal hormonal findings by immunohistochemistry and discussed their usefulness as immunohistochemical markers for diagnosis.
  • Ad4BP/SF-1 and DAX-1 underwent immunohistochemical study using needle biopsy specimens from the retroperitoneal tumor or metastatic tumor of these patients to diagnose primary adrenocortical carcinoma.
  • Ad4BP/SF-1 immunoreactivity was observed in the carcinoma cells of 2 patients, but not in the others, whereas DAX-1 immunoreactivity was observed in the carcinoma cells of all 4 patients.
  • CONCLUSION: The expressions of Ad4BP/SF-1 and DAX-1 are considered essential to maintain the biological characteristics of adrenocortical cells even without abnormal hormonal findings or even after malignant transformation and metastasis.
  • These markers are useful to distinguish other retroperitoneal tumors, especially in patients with bulky tumors, and to diagnose the metastatic site of origin as adrenocortical carcinoma in patients clinically presenting with widespread metastasis.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis. Biomarkers, Tumor / analysis. DNA-Binding Proteins / analysis. Receptors, Retinoic Acid / analysis. Repressor Proteins / analysis. Steroidogenic Factor 1 / analysis
  • [MeSH-minor] DAX-1 Orphan Nuclear Receptor. Humans. Immunohistochemistry. Middle Aged. Retroperitoneal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18824868.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DAX-1 Orphan Nuclear Receptor; 0 / DNA-Binding Proteins; 0 / NR0B1 protein, human; 0 / NR5A1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Repressor Proteins; 0 / Steroidogenic Factor 1
  •  go-up   go-down


82. Wang FF, Chang YH, Pan CC, Tu DG, Won JG: Unusual visualization of an adrenal carcinoma on NP-59 scintiscan. J Formos Med Assoc; 2006 Apr;105(4):340-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual visualization of an adrenal carcinoma on NP-59 scintiscan.
  • [Iodine-131]6-beta-iodomethylnorcholesterol (NP-59) visualization of adrenocortical carcinoma is unusual.
  • Magnetic resonance imaging disclosed a 9-cm right adrenal mass.
  • NP-59 adrenal scanning displayed unilateral uptake of tracer and no visualization of the contralateral adrenal gland.
  • Exploratory laparotomy revealed adrenocortical carcinoma.
  • Visualization of an adrenal tumor on NP-59 scintiscan is an unusual finding, which cannot exclude the possibility of malignancy.

  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618615.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 4964P6T9RB / Aldosterone; 55623-03-5 / Adosterol; 57B09Q7FJR / Dehydroepiandrosterone Sulfate
  •  go-up   go-down


83. Szücs N, Gláz E, Varga I, Tóth M, Kiss R, Patócs A, Jakab C, Perner F, Járay J, Horányi J, Dabasi G, Molnár F, Major L, Füto L, Rácz K, Tulassay Z: [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases]. Orv Hetil; 2006 Jan 15;147(2):51-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
  • The disease has been described by Jerome W.
  • Conn in 1955; since that time there has been a great progress in the knowledge concerning the prevalence, diagnostics and treatment of the disease.
  • METHODS: The efficacy of different methods used for the diagnosis, the frequency of the different subtypes of primary aldosteronism, as well as the surgical outcomes in patients with surgically treated subtypes of primary aldosteronism were studied.
  • Other subtypes of primary hyperaldosteronism occurred less frequently (unilateral primary adrenocortical hyperplasia in 5 patients and adrenocortical carcinoma in one patient).
  • For the diagnosis of familial hyperaldosteronism type I, molecular biological studies of the aldosterone-synthase/11beta-hydroxylase gene chimera were carried out in 30 patients but none of them showed the presence of the chimeric gene.
  • When comparing the clinical parameters of patients with aldosterone-producing adenoma and idiopathic hyperaldosteronism, no significant differences were found in the time period between the diagnosis of hypertension and the diagnosis of primary aldosteronism, or in the systolic and diastolic blood pressure values.
  • To confirm the diagnosis and to differentiate the subtypes of primary aldosteronism, the postural test combined with furosemide administration was performed in the majority of patients.
  • In cases of adrenocortical adenomas not or not clearly detectable by radiological imaging techniques, as well as in cases with bilateral adrenocortical adenomas, selective adrenal vein sampling was performed (n = 55).
  • Histology and postoperative hormone results confirmed the preoperative diagnosis in all operated patients.
  • [MeSH-major] Adenoma / surgery. Adrenal Cortex Neoplasms / surgery. Aldosterone / secretion. Hyperaldosteronism / diagnosis. Hyperaldosteronism / therapy. Mineralocorticoid Receptor Antagonists / therapeutic use

  • Genetic Alliance. consumer health - Primary aldosteronism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509213.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Mineralocorticoid Receptor Antagonists; 0 / Mutant Chimeric Proteins; 4964P6T9RB / Aldosterone; EC 1.14.15.4 / Cytochrome P-450 CYP11B2; EC 1.14.15.4 / Steroid 11-beta-Hydroxylase
  •  go-up   go-down


84. Kirshtein B, Yelle JD, Moloo H, Poulin E: Laparoscopic adrenalectomy for adrenal malignancy: a preliminary report comparing the short-term outcomes with open adrenalectomy. J Laparoendosc Adv Surg Tech A; 2008 Feb;18(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic adrenalectomy for adrenal malignancy: a preliminary report comparing the short-term outcomes with open adrenalectomy.
  • BACKGROUND: The laparoscopic approach to adrenal malignancy remains a topic of debate.
  • RESULTS: Twenty-six cases were identified: 19 women and 7 men with a median age of 48 years (range, 20-81) underwent 12 open (8 adrenocortical carcinoma [ACC] and 4 metastases) and 14 laparoscopic adrenalectomies (5 ACC, 8 metastases, and 1 lymphoma).
  • There was no difference in age, sex, American Society of Anesthesiologists status or diagnosis between the two groups, but patients in the laparoscopic group had a higher body mass index.
  • CONCLUSIONS: Laparoscopic adrenalectomy is both feasible and safe for some malignant tumors of the adrenal gland in experienced hands.
  • Careful selection, preoperative staging, and respect for oncologic principles are important considerations in choosing laparoscopic surgery for primary and secondary adrenal malignancy.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Carcinoma / surgery. Laparoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18266573.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Rodgers SE, Evans DB, Lee JE, Perrier ND: Adrenocortical carcinoma. Surg Oncol Clin N Am; 2006 Jul;15(3):535-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma.
  • ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with the improvement in patient survival.
  • Even with appropriated diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies.
  • Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease.
  • [MeSH-major] Adrenal Cortex Neoplasms. Adrenocortical Carcinoma

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882496.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IGF2 protein, human; 0 / Proteins; 67763-97-7 / Insulin-Like Growth Factor II; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 85
  •  go-up   go-down


86. Lin MT, Shieh JJ, Chang JH, Chang SW, Chen TC, Hsu WH: Early detection of adrenocortical carcinoma in a child with Li-Fraumeni syndrome. Pediatr Blood Cancer; 2009 Apr;52(4):541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early detection of adrenocortical carcinoma in a child with Li-Fraumeni syndrome.
  • We report an early detection of cancer in a child with Li-Fraumeni syndrome.
  • The younger sister at risk was followed, and an asymptomatic adrenal cortical carcinoma was detected 3 years later.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis. Early Detection of Cancer. Genetic Predisposition to Disease. Li-Fraumeni Syndrome / genetics

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 19101993.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


87. Gaisa NT, Klöppel G, Brehmer B, Neulen J, Stephan P, Knüchel R, Donner A: [Virilizing adrenal ganglioneuroma : A rare differential diagnosis in testosterone secreting adrenal tumours]. Pathologe; 2009 Sep;30(5):407-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Virilizing adrenal ganglioneuroma : A rare differential diagnosis in testosterone secreting adrenal tumours].
  • [Transliterated title] Virilisierendes Ganglioneurom der Nebenniere : Eine seltene Differenzialdiagnose testosteronproduzierender Nebennierentumoren.
  • Testosterone secreting tumours of the adrenal glands are usually adrenal carcinomas or adenomas.
  • Here we report the rare case of an adrenal ganglioneuroma with ectopic Leydig cells, a so-called virilizing adrenal ganglioneuroma.
  • Clinically it is characterized by symptoms of virilization, histologically by the occurrence of a population of eosinophilic cells.
  • In the absence of crystalloids of Reinke this cell population can be identified as Leydig cells based on positive immunohistochemical staining of inhibin and calretinin.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / secretion. Ganglioneuroma / pathology. Ganglioneuroma / secretion. Testosterone / secretion. Virilism / pathology
  • [MeSH-minor] Adrenal Cortex / pathology. Adrenal Gland Diseases / pathology. Adrenal Gland Diseases / surgery. Adrenalectomy. Aged. Biomarkers, Tumor / analysis. Calbindin 2. Choristoma / pathology. Choristoma / surgery. Diagnosis, Differential. Female. Humans. Inhibins / analysis. Laparoscopy. Leydig Cells. Male. S100 Calcium Binding Protein G / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Chir Belg. 1993 Jul-Aug;93(4):181-4 [8237234.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):159-62 [12051635.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:421-5 [13749451.001]
  • [Cites] Am J Surg Pathol. 1983 Oct;7(7):699-705 [6685441.001]
  • [Cites] Pathologe. 2003 Jul;24(4):280-6 [14513275.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):774-9 [9720507.001]
  • [Cites] Ann Diagn Pathol. 2008 Feb;12(1):29-32 [18164412.001]
  • [Cites] JAMA. 1978 May 26;239(21):2273-4 [650810.001]
  • (PMID = 19396442.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 3XMK78S47O / Testosterone; 57285-09-3 / Inhibins
  •  go-up   go-down


88. Vuorenoja S, Rivero-Muller A, Kiiveri S, Bielinska M, Heikinheimo M, Wilson DB, Huhtaniemi IT, Rahman NA: Adrenocortical tumorigenesis, luteinizing hormone receptor and transcription factors GATA-4 and GATA-6. Mol Cell Endocrinol; 2007 Apr 15;269(1-2):38-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical tumorigenesis, luteinizing hormone receptor and transcription factors GATA-4 and GATA-6.
  • Luteinizing hormone (LH/hCG) responsiveness of normal and pathological human adrenal glands as well as the possibility of constitutive expressions of luteinizing hormone receptor (LHR) in adrenal cortex has been reported.
  • Some recent studies showed a correlation between the LHR and abundant GATA-4 expression in both metastasizing and non-metastasizing human adrenocortical tumors, but not in normal adrenals, implicating the putative relevance of LHR and GATA-4 for adrenocortical pathophysiology.
  • However, the physio- and pathophysiological significance of LHR and GATA-4 in the mechanism of adrenocortical tumorigenesis remains unclear.
  • The paucity of suitable models for adrenal tumorigenesis makes the establishment of proper animal models highly important.
  • LHR expression in the murine adrenal gland is an exception and not found in wild-type (WT) animal.
  • We have previously shown that ectopic LHR expression in the murine adrenal gland can be induced by chronically elevated LH levels.
  • We have generated a gonadotropin-responsive adrenal tumor model in gonadectomized transgenic (TG) mice expressing the inhibin alpha promoter/Simian Virus 40 T antigen transgene (inhalpha/Tag).
  • Given the induction of expression and regulation of GATA-4 and GATA-6 zinc finger transcription factors in the gonads by gonadotropins, this review will explore their relationship to LHR expression and their role in adrenocortical tumorigenesis.
  • A functional link between LHR and GATA-4 actions in the adrenal pathophysiology is proposed.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Carcinoma / genetics. GATA4 Transcription Factor / physiology. GATA6 Transcription Factor / physiology. Receptors, LH / physiology
  • [MeSH-minor] Animals. Disease Models, Animal. Humans. Inhibins / genetics. Mice. Mice, Transgenic

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337116.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / GATA4 Transcription Factor; 0 / GATA4 protein, human; 0 / GATA6 Transcription Factor; 0 / GATA6 protein, human; 0 / Receptors, LH; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins
  • [Number-of-references] 87
  •  go-up   go-down


89. Behrend EN, Weigand CM, Whitley EM, Refsal KR, Young DW, Kemppainen RJ: Corticosterone- and aldosterone-secreting adrenocortical tumor in a dog. J Am Vet Med Assoc; 2005 May 15;226(10):1662-6, 1659
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corticosterone- and aldosterone-secreting adrenocortical tumor in a dog.
  • An adrenal gland tumor was visualized via ultrasonography and computed tomography.
  • Histologic examination confirmed that the mass was an adrenocortical carcinoma.
  • Excess adrenal secretion of corticosterone was hypothesized to be the cause of the signs of glucocorticoid excess.
  • Treatment with mitotane was instituted and successful for a period of 4-months until the dog was euthanatized for neurologic problems that were most likely unrelated to endocrine disease.
  • [MeSH-major] Adrenal Cortex Neoplasms / veterinary. Aldosterone / secretion. Antineoplastic Agents, Hormonal / therapeutic use. Corticosterone / secretion. Dog Diseases / diagnosis. Mitotane / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906564.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 4964P6T9RB / Aldosterone; 78E4J5IB5J / Mitotane; W980KJ009P / Corticosterone
  •  go-up   go-down


90. Patel VV, Shah DS, Raychaudhari CR, Patel KB: Giant non-functioning adrenocortical carcinoma: A rare childhood tumor. Indian J Med Paediatr Oncol; 2010 Apr;31(2):65-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant non-functioning adrenocortical carcinoma: A rare childhood tumor.
  • Adrenocortical carcinoma (ACC) is a rare malignancy, especially in children.
  • Empty left renal fossa and compensatory enlarged right kidney were seen.
  • With a stage IV disease, the patient died after 2 months from diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiographics. 1999 Jul-Aug;19(4):989-1008 [10464805.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):755-9 [11222220.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Pediatr Pathol Mol Med. 2003 Sep-Oct;22(5):405-10 [14692192.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):838-45 [14990639.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):657-66 [16172198.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2027-31 [9215267.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):108-13 [17277000.001]
  • [Cites] Neth J Med. 2007 Feb;65(2):55-60 [17379929.001]
  • [Cites] Oncology. 1988;45(1):15-7 [3340389.001]
  • [Cites] Jpn J Surg. 1985 Nov;15(6):477-82 [3831502.001]
  • [Cites] Jpn J Clin Oncol. 2009 Mar;39(3):183-5 [19168875.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • (PMID = 21209768.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2970938
  • [Keywords] NOTNLM ; Adrenocortical carcinoma / adrenocortical tumor / nonfunctioning
  •  go-up   go-down


91. Pan CC, Chen PC, Tsay SH, Ho DM: Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol; 2005 Dec;13(4):347-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique.
  • The differential diagnoses of hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and adrenocortical carcinoma (ACC) are sometimes difficult due to their overlapping histologic features.
  • Immunohistochemistry is a helpful adjunct in supporting the histologic diagnosis.
  • Proper selection of immunohistochemical stains aid in the differential diagnosis of the three neoplasms.


92. Tissier F: [Pathology of adrenocortical tumors: review and recent data]. Ann Endocrinol (Paris); 2009 Jun;70(3):179-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathology of adrenocortical tumors: review and recent data].
  • [Transliterated title] Anatomie pathologique des tumeurs corticosurrénaliennes de l'adulte : état des lieux et données récentes.
  • Most adrenocortical tumors are benign; adrenocortical carcinomas are rare but their prognosis is poor and their therapeutic is sparse.
  • In most adrenocortical tumors, the morphological approach brings sufficient elements to establish the differential diagnosis between a benign and a malignant tumor but in few cases, it is insufficient.
  • Moreover, morphology is limited for predicting prognosis of adrenocortical carcinomas.
  • These genetics findings already have repercussions for the patients in the development of molecular markers for diagnosis and prognosis and in the future they could help in the development of new morphological approaches, in particular immunohistochemical approaches.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298951.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cyclin E; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; 67763-97-7 / Insulin-Like Growth Factor II
  • [Number-of-references] 77
  •  go-up   go-down


93. Hirai T, Tsujihata M, Ueda T, Nonomura N, Okuyama A: A case of polymyositis associated with adrenal carcinoma. Int J Urol; 2007 Oct;14(10):952-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of polymyositis associated with adrenal carcinoma.
  • The association between idiopathic inflammatory myositis and cancer is well recognized.
  • Most descriptions have been of dermatomyositis-associated cancer, however, a few have been of polymyositis-associated adrenal cancer.
  • Here, we report a 69-year-old man in whom polymyositis-associated adrenal cancer was diagnosed.
  • Physical examination and electrophysiological studies revealed an abnormality of the proximal muscles.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Carcinoma / diagnosis. Polymyositis / diagnosis

  • Genetic Alliance. consumer health - Polymyositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17880299.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.7.3.2 / Creatine Kinase
  •  go-up   go-down


94. Lynch HT, Silva E, Snyder C, Lynch JF: Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J; 2008 Jan-Feb;14(1):3-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes.
  • Hereditary breast cancer (HBC) accounts for as much as 10% of the total BC burden.
  • Confounding factors include its phenotypic and genotypic heterogeneity, given the association of HBC with a plethora of differing cancer syndromes.
  • Its most common occurrence is its association with ovarian cancer in the so-called hereditary breast-ovarian cancer syndrome due to BRCA1 and BRCA2 mutations.
  • More rarely, it occurs in the Li-Fraumeni syndrome, caused by a p53 germline mutation, in which markedly early-onset BC is found in association with brain tumors, sarcomas, leukemia, lymphoma, malignant melanoma, and adrenal cortical carcinoma.
  • We postulate that increasing knowledge about the genetics of BC may have partially contributed to the identification of high-risk patients who thereby may have benefited significantly from early diagnosis.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Genetic Predisposition to Disease. Li-Fraumeni Syndrome / diagnosis. Li-Fraumeni Syndrome / genetics

  • Genetic Alliance. consumer health - Hereditary Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086272.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1U01 CA 86389
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
  • [Number-of-references] 38
  •  go-up   go-down


95. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, Da Rocha JC, Vettore AL, Hainaut P: The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett; 2007 Jan 8;245(1-2):96-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A TP53 germline mutation, R337H, has been previously described in children from southern Brazil with adrenocortical tumours but no documented familial history of other cancers.
  • Families with the R337H mutation presented a wide spectrum of tumours, including breast cancers (30.4%), brain cancers (10.7%), soft tissue sarcomas (10.7%) and adrenocortical carcinomas (8.9%).
  • Testing of 53 Brazilian subjects with no cancer history showed that R337H was not a common polymorphism in that population.
  • Moreover, loss of heterozygocity with retention of the R337H allele was observed in a breast adenocarcinoma, supporting a role for this mutation in breast tumorigenesis.
  • [MeSH-minor] Base Sequence. Brazil. DNA Mutational Analysis. Female. Genetic Predisposition to Disease / genetics. Humans. Male. Mutation, Missense. Neoplastic Syndromes, Hereditary / genetics. Neoplastic Syndromes, Hereditary / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Lett. 2007 Mar 18;247(2):353-5; author reply 356-8 [16750598.001]
  • (PMID = 16494995.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


96. Mete O, Kapran Y, Güllüoğlu MG, Kiliçaslan I, Erbil Y, Senyürek YG, Dizdaroğlu F: Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. Virchows Arch; 2010 May;456(5):515-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas.
  • In the evaluation of retroperitoneal masses, the practicing pathologist faces a dilemma when making a diagnosis based on histology given the often overlapping morphologic appearances of the adrenocortical carcinoma, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC).
  • CD10 is expressed in a membranous fashion in the vast majority of clear cell RCCs; therefore, it is widely used for distinction from its mimics.
  • However, its expression is not well-investigated in adrenal cortical tumors.
  • We examined CD10 expression in 47 surgically resected adrenocortical tumors (26 adenomas and 21 carcinomas) and compared with 20 clear cell RCCs and 25 HCCs.
  • Twenty HCCs (80%), 18 RCCs (90%), 11 adrenocortical carcinomas (52%), and 18 adrenocortical adenomas (69%) were positive for CD10.
  • HCCs were characterized by a canalicular staining, and clear cell RCCs exhibited membranous or mixed membranous-cytoplasmic staining.
  • Adrenocortical tumors displayed mainly cytoplasmic staining.
  • Four adrenocortical carcinomas and one adenoma also displayed the membranous staining pattern.
  • Despite the relatively small number of samples, our preliminary results revealed that adrenocortical tumors may express CD10 (Clone: 56C6).
  • The most important point from this paper is the fact that anti-CD10 expression has not been previously reported in adrenocortical carcinomas.
  • This suggests that CD10 does not seem to be a useful marker for discriminating clear cell RCCs from adrenocortical tumors since CD10 expression does not rule out the possibility of adrenocortical tumors.
  • This feature should be kept in mind when constructing an antibody panel for an epithelial tumor that involves the adrenal gland and kidney, especially in small biopsy specimens.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Neprilysin / biosynthesis
  • [MeSH-minor] Adult. Antigens, Neoplasm / analysis. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / immunology. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / immunology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2008 Jan;52(2):119-29 [17825057.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):77-82 [9916921.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1205-9 [14681320.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2178-83 [19318454.001]
  • [Cites] Horm Res. 2008;70(5):294-9 [18824868.001]
  • [Cites] Histopathology. 2004 Nov;45(5):452-9 [15500648.001]
  • [Cites] J Clin Pathol. 2000 Mar;53(3):206-11 [10823140.001]
  • [Cites] Pathol Int. 2009 Jan;59(1):38-43 [19121090.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):374-82 [10705818.001]
  • [Cites] J Pediatr Hematol Oncol. 2010 Jan;32(1):2-3 [20051779.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):413-4 [12604902.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):203-10 [10680888.001]
  • [Cites] Histopathology. 2004 Nov;45(5):460-7 [15500649.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jan 22;171(1-2):5-7 [11165004.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):347-52 [16280664.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):289-97 [18852677.001]
  • [Cites] Pathology. 2009 Feb;41(2):191-3 [19152193.001]
  • (PMID = 20390424.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


97. Amar L, Plouin PF, Steichen O: Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis; 2010;5:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unilateral aldosterone hypersecretion is caused by an aldosterone-producing adenoma (also known as Conn's adenoma and aldosteronoma), primary unilateral adrenal hyperplasia and rare cases of aldosterone-producing adrenocortical carcinoma.
  • Its prevalence in referred hypertensive populations is estimated to be between 6 and 13%, of which 1.5 to 5% have an aldosterone-producing adenoma or primary unilateral adrenal hyperplasia.
  • The differential diagnosis of hypokalemic hypertension with low renin includes mineralocorticoid excess, with the mineralocorticoid being cortisol or 11-deoxycorticosterone, apparent mineralocorticoid excess, pseudo-hypermineralocorticoidism in Liddle syndrome or exposure to glycyrrhizic acid.
  • Once the diagnosis is confirmed, adrenal computed tomography is performed for all patients.
  • If surgery is considered, taking into consideration the clinical context and the desire of the patient, adrenal vein sampling is performed to detect whether or not aldosterone hypersecretion is unilateral.
  • [MeSH-major] Adrenocortical Adenoma / diagnosis. Adrenocortical Adenoma / metabolism. Aldosterone / metabolism. Hyperaldosteronism / diagnosis. Hyperaldosteronism / surgery

  • Genetic Alliance. consumer health - Primary aldosteronism.
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2005 Apr 19;45(8):1243-8 [15837256.001]
  • [Cites] J Urol. 2005 Jul;174(1):40-3 [15947573.001]
  • [Cites] Radiographics. 2005 Oct;25 Suppl 1:S143-58 [16227488.001]
  • [Cites] Surgery. 2005 Dec;138(6):1009-16; discussion 1016-7 [16360385.001]
  • [Cites] J Hum Hypertens. 2006 Feb;20(2):129-36 [16292348.001]
  • [Cites] Am Surg. 2005 Oct;71(10):864-9 [16468537.001]
  • [Cites] J Hypertens. 2006 Feb;24(2):371-9 [16508586.001]
  • [Cites] JAMA. 2006 Jun 14;295(22):2638-45 [16772627.001]
  • [Cites] J Am Coll Cardiol. 2006 Dec 5;48(11):2293-300 [17161262.001]
  • [Cites] Hypertension. 2007 Apr;49(4):846-56 [17296870.001]
  • [Cites] Hypertens Res. 2007 Feb;30(2):111-7 [17460380.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):607-18 [17492946.001]
  • [Cites] J Hypertens. 2007 Jul;25(7):1433-42 [17563566.001]
  • [Cites] ANZ J Surg. 2007 Sep;77(9):768-73 [17685956.001]
  • [Cites] J Hypertens. 2007 Sep;25(9):1751-62 [17762635.001]
  • [Cites] Ann Endocrinol (Paris). 2007 Oct;68(5):349-56 [17368420.001]
  • [Cites] Am J Hypertens. 2007 Dec;20(12):1334-7 [18047926.001]
  • [Cites] Surgery. 2007 Dec;142(6):921-9; discussion 921-9 [18063077.001]
  • [Cites] J Vasc Interv Radiol. 2008 Jan;19(1):66-71 [18192469.001]
  • [Cites] Arch Intern Med. 2008 Jan 14;168(1):80-5 [18195199.001]
  • [Cites] Ann Surg. 2008 Mar;247(3):511-8 [18376197.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):133-54 [18292466.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1366-71 [18198224.001]
  • [Cites] Hypertension. 2008 May;51(5):1366-71 [18347224.001]
  • [Cites] Lancet. 2008 Jun 7;371(9628):1921-6 [18539224.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Jul;69(1):20-8 [18284637.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62 [18413427.001]
  • [Cites] Horm Metab Res. 2008 Jul;40(7):435-41 [18493881.001]
  • [Cites] J Hypertens. 2008 Sep;26(9):1816-23 [18698217.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81 [18552288.001]
  • [Cites] Chirurg. 2008 Nov;79(11):1087-94; quiz 1095-6 [18941729.001]
  • [Cites] Surgery. 2008 Dec;144(6):926-33; discussion 933 [19040999.001]
  • [Cites] Clin Endocrinol (Oxf). 2009 Jan;70(1):14-7 [19128364.001]
  • [Cites] Ann Surg. 2009 Feb;249(2):318-21 [19212188.001]
  • [Cites] Hypertension. 2009 Apr;53(4):605-10 [19221213.001]
  • [Cites] J Hum Hypertens. 2009 Apr;23(4):292-4 [18754018.001]
  • [Cites] Clin Chem. 2009 May;55(5):867-77 [19264850.001]
  • [Cites] Biomed Pharmacother. 2000 Jun;54 Suppl 1:164s-168s [10915016.001]
  • [Cites] Ann Intern Med. 2009 Sep 1;151(5):329-37 [19721021.001]
  • [Cites] Hypertension. 2010 Jan;55(1):83-9 [19933925.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Biomed Pharmacother. 2000 Jun;54 Suppl 1:83s-85s [10914999.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1066-71 [11238487.001]
  • [Cites] Am J Kidney Dis. 2001 Apr;37(4):699-705 [11273868.001]
  • [Cites] Ann Intern Med. 2001 Aug 21;135(4):258-61 [11511140.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4292-8 [11549664.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6762-7 [11559548.001]
  • [Cites] Am J Med Sci. 2001 Dec;322(6):302-7 [11780687.001]
  • [Cites] Metabolism. 2002 Mar;51(3):350-5 [11887172.001]
  • [Cites] Endocrinol Metab Clin North Am. 2002 Sep;31(3):619-32, xi [12227124.001]
  • [Cites] Am J Hypertens. 2002 Oct;15(10 Pt 1):896-902 [12372677.001]
  • [Cites] Hypertension. 2002 Dec;40(6):892-6 [12468575.001]
  • [Cites] Hypertension. 2002 Dec;40(6):897-902 [12468576.001]
  • [Cites] J Urol. 2003 Jan;169(1):32-5 [12478096.001]
  • [Cites] Nucl Med Commun. 2003 Jun;24(6):683-8 [12766605.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2489-94 [12788844.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3637-44 [12915648.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1045-50 [15001583.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]
  • [Cites] Mol Cell Endocrinol. 2004 Mar 31;217(1-2):33-9 [15134798.001]
  • [Cites] Br J Surg. 2004 Oct;91(10):1259-74 [15376201.001]
  • [Cites] Arch Intern Med. 1981 Nov;141(12):1589-93 [7030245.001]
  • [Cites] Am J Cardiol. 1987 Oct 1;60(10):820-5 [3661395.001]
  • [Cites] J Hypertens Suppl. 1987 Dec;5(5):S103-6 [2832571.001]
  • [Cites] J Hum Hypertens. 1988 Oct;2(3):187-9 [3236322.001]
  • [Cites] Am J Hypertens. 1990 Jul;3(7):576-82 [2194512.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):323-7 [1619026.001]
  • [Cites] Surgery. 1992 Dec;112(6):987-93 [1455323.001]
  • [Cites] J Urol. 1993 Nov;150(5 Pt 1):1365-8 [8411401.001]
  • [Cites] Clin Radiol. 1994 Jul;49(7):453-5 [8088036.001]
  • [Cites] Clin Exp Pharmacol Physiol. 1994 Apr;21(4):319-22 [7923899.001]
  • [Cites] Ann Intern Med. 1994 Dec 1;121(11):877-85 [7978702.001]
  • [Cites] J Clin Invest. 1995 Nov;96(5):2236-46 [7593610.001]
  • [Cites] Radiology. 1996 Feb;198(2):309-12 [8596821.001]
  • [Cites] J Pediatr Surg. 1996 Mar;31(3):430-2 [8708918.001]
  • [Cites] Surgery. 1998 Dec;124(6):1128-33 [9854594.001]
  • [Cites] Lancet. 1999 Apr 17;353(9161):1341-7 [10218547.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):628-31; discussion 631-2 [10367872.001]
  • [Cites] Ann Intern Med. 1999 Jul 20;131(2):105-8 [10419425.001]
  • [Cites] J Lab Clin Med. 1955 Jan;45(1):3-17 [13233623.001]
  • [Cites] JAMA. 1964 Oct 19;190:213-21 [14246592.001]
  • [Cites] Lancet. 2005 Jan 15-21;365(9455):217-23 [15652604.001]
  • [Cites] Surgery. 2004 Dec;136(6):1227-35 [15657580.001]
  • (PMID = 20482833.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone
  • [Number-of-references] 83
  • [Other-IDs] NLM/ PMC2889888
  •  go-up   go-down


98. Karim RZ, Wills EJ, McCarthy SW, Scolyer RA: Myxoid variant of adrenocortical carcinoma: report of a unique case. Pathol Int; 2006 Feb;56(2):89-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxoid variant of adrenocortical carcinoma: report of a unique case.
  • Myxoid variant of adrenocortical carcinomas (ACC) are rare, there being only 11 cases in the literature to date.
  • Reported herein are the findings of a case, which in contrast to all previously reported myxoid ACC, was devoid of typical non-myxoid areas.
  • The patient was a 61-year-old man in whom a left adrenal mass was detected during investigation of Cushing's syndrome.
  • The adrenal was replaced by malignant cells and expanses of myxoid material.
  • The ultrastructural features of the cells were typical of adrenal cortical differentiation.
  • The differential diagnosis of myxoid ACC includes extraskeletal myxoid chondrosarcoma, chordoma, myxoid adenocarcinoma, myxoma, lipomatous tumors, nerve sheath tumors, smooth muscle tumors, gastrointestinal stromal tumor and other sarcomas.
  • The presence of myxoid material in a retroperitoneal lesion raises a broad differential diagnosis in which myxoid adrenocortical neoplasms should be included.
  • Clinicoradiological correlation may be helpful, but special stains, immunohistochemistry and ultrastructural examination may be necessary to establish the diagnosis.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Antigens, Neoplasm. Chordoma / diagnosis. Chordoma / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. MART-1 Antigen. Male. Microscopy, Electron. Middle Aged. Myxoma / diagnosis. Myxoma / pathology. Neoplasm Proteins / analysis. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / pathology. Synaptophysin / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445821.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / Synaptophysin; 0 / Vimentin
  •  go-up   go-down


99. Emerson RE, Ulbright TM: The use of immunohistochemistry in the differential diagnosis of tumors of the testis and paratestis. Semin Diagn Pathol; 2005 Feb;22(1):33-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of immunohistochemistry in the differential diagnosis of tumors of the testis and paratestis.
  • OCT4 is virtually 100% sensitive and specific for seminoma, embryonal carcinoma, and intratubular germ cell neoplasia, unclassified type.
  • Inhibin-alpha, among testicular tumors, is limited to those in the sex cord-stromal category or those having adrenocortical-type differentiation (testicular tumor of the adrenogenital syndrome) or of trophoblastic lineage.
  • [MeSH-major] Immunohistochemistry. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Humans. Male. Neoplasm Metastasis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512598.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 137
  •  go-up   go-down


100. Happel B, Heinz-Peer G: Enhancement characteristics of pheochromocytomas. Radiology; 2006 Jan;238(1):373; author reply 373-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adrenal Cortex Neoplasms / radiography. Adrenal Gland Neoplasms / radiography. Adrenocortical Carcinoma / radiography. Pheochromocytoma / radiography. Tomography, X-Ray Computed / methods






Advertisement